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Abstract
rumpshaker (rsh) is a recessive X-linked point mutation (He TTir) which produces 
dysmyelination in the murine central nervous system. This study compared the 
behavioural and pathological aspects o f the mutation on the C57BL/6 background 
(C57 rsh) to those on the C3H background (C3H rsh). C3H rsh is more mildly 
affected behaviourally and pathologically than C57 rsh. C3H rsh has normal 
longevity and is also able to reproduce successfully. In contrast, C57 rsh develops 
seizures at about postnatal day (P25) and dies between 4-5 weeks.
Both C3H rsh and C57 rsh fail to myelinate properly and develop dysmyelination in 
the CNS with the C57 rsh heing more severely affected. This feature coincides with 
stages of active myelinogenesis. Western blot analyses strongly supports this 
finding as the levels o f major myelin proteins are considerably reduced in the C57 
rsh compared with C3H rsh.
There are significant differences between the mutants and their normal littermates 
on both genetic backgrounds and between the two mutants themselves. The total 
glial density is notably increased in the C57 rsh which is coupled with an increase 
in dead cells in the cervical spinal cord white matter. In vivo BrdU labelling shows 
that proliferation rates and the number of dividing cells are markedly greater in the 
C57 rsh. In spite o f the differences between the two strains, C3H rsh and C57 rsh 
both maintain the numbers of oligodendrocytes. Nonetheless, the activated 
macrophage/microglial cells are more marked in C57 rsh CNS white matter than 
C3H rsh. Surprisingly, the actual number of astrocytes remained unchanged, 
however, their activation is represnted by an increase in GFAP, as shown by 
immunostaining and western immunoblotting.
This study suggests that there is no direct causal link between the dysmyelination 
and the oligodendrocyte number or even the death of oligodendrocye lineages. 
However, it provides evidence to support the notion that the severity o f the disease 
correlates with the number of apoptotic cells, the reduced amount o f myelin and the 
activation of microglia/macrophages.
While the rsh mutation on either genetic background is similarly heritable, the 
differences in phenotypes are likely attributable to differences in genetic 
background, thus suggesting the importance of modifying loci in determining the 
phenotype.
To my wife, Abdulrahman and faie
Ill
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1. Introduction
1.1 Area of the study
The rumpshaker mutation causes a generalised defect o f myelination throughout the 
CNS, although different regions show a variation in temporal change, consistent 
with the pattern of myelination. We chose to make the majority of our quantitative 
studies in the cervical spinal cord. This region was selected as it represents an area 
in which cell counts and myelin measurements can be performed accurately and is 
also a region that we have used frequently for study of normality and disease. Non- 
quantitative assessments of pathology were made in various brain regions.
1.2 CNS structure
The gross structure can be divided into the brain and spinal cord with the tonner 
being subdivided further. As the majority o f this study is devoted to the spinal cord, 
this region will be emphasised. The spinal cord consists of the central grey matter 
and the peripheral white matter. The grey matter is subdivided into dorsal and 
ventral horns and intermediate regions although more complex laminar 
arrangements based on cytoarchitecture are also used. The grey matter contains the 
neuronal perikarya, glial cells and blood vessels. The white matter is classically 
divided into dorsal, lateral and ventral columns or funiculi. In normal mice, the 
white matter consists o f myelinated fibres with occasional interspersed 
unmyelinated axons and the intervening neuropil of glial cells and blood vessels. 
The glial cells consist o f the astrocytes and oligodendrocytes, which constitute the 
macroglia, and the microglia; undifferentiated glial progenitors are also present. A 
fine extracellular matrix also exists throughout the neuropil although this is difficult 
to visualise with most conventional staining methods.
1.3 Glial development
The origin of glial cells, mainly oligodendrocytes and astrocytes, has been proposed 
to be from a pool of neuroepithelial cells in the sub-ventricular zone of the 
developing spinal cord (Hirano and Goldman, 1988; Noll and Miller, 1993; Timsit
et aL^ 1995; Miller et a l ,  1997; Chandross et a l ,  1999) although the nature of the 
glial precursor cell(s) is still being debated. Several studies support the view that 
separate distinct precursors exist for oligodendrocytes and astrocytes (Phillips, 
1973; Lord and Duncan, 1987; Pamavelas, 1999) although evidence for a common 
origin has been produced. Shortly after birth, cells can be classified into 
oligodendroblasts, astroblasts, and undifferentiated precursors (Prayoonwiwat and 
Rodriguez, 1993).
Waves of oligodendroglial progenitors migrate from the ventral zone and colonise 
the white matter tracts (Noll and Miller, 1993; Timsit et a l ,  1995; Miller et a l ,
1997). At a morphological level, light and dark oligodendrocytes have been 
described. The former proliferate before myelination and the later predominate at 
the stage of myelination (Arenella and Herndon, 1984; Lord and Duncan, 1987; 
Hirano and Goldman, 1988; Yoshida, 1997). Glial cell development and 
differentiation, however, are regulated through different factors (Scarlato et a l ,  
2000). Apoptosis which is a physiological phenomenon in normal development has 
been reported among these developing progenitors (Barres et a l ,  1992).
1.4 The oligodendrocytes
1.4,1 Origin of oligodendrocytes
The issue of the origin of the founder precursor of oligodendrocytes remains 
controversial. It is accepted that in the spinal cord the oligodendrocyte lineage arises 
from the sub-ventricular zone in the ventral potion of the embryonic cord. 
Currently, the basic helix-loop-helix transcription factors Oligl and 01ig2 (Zhou et 
a l,  2000) together with Nkx2.2 (Xu et a l ,  2000) define the earliest recognisable 
cells of the oligodendrocyte lineage (Wegner, 2001; Woodruff et a l ,  2001). The 
majority of early oligodendrocyte progenitors express the alpha receptor for 
platelet-derived growth factor A (PDGFRa), which has been used as a marker for 
these cells (Pringle and Richardson, 1993; Nishiyama et a l ,  1996; Hall et a l ,  1996) 
and the myelin protein 2 '3 '-cyclic nucleotide 3-phosphodiestersae (CNP) (Yu et a l ,  
1994). A small, and possibly distinct, sub-population express the DM20 isoform of 
PLP and lack the PDGFRa (Timsit et a l ,  1995; Dickinson et a l ,  1996; Spassky et 
a l ,  1998; Spassky et a l ,  2000). Still later in development, progenitors express NG2 
proteoglycan (Nishiyama et a l ,  1996), a marker that also exists on adult progenitor 
cells.
Sonic hedgehog (shh) has been shown to specify a common precursor for 
oligodendrocytes (Richardson et a l ,  1997). The use of retroviral lineage marker has
provided excellent evidence for the precursors of oligodendrocyte lineages in the 
brain (Small et a l ,  1987; Leber et a l ,  1990; Levison and Goldman, 1993; Levison 
et a l ,  1993).
All these markers strongly support the notion that oligodendrocytes are descendants 
of genetically similar precursors.
1.4.2 Differentiation and development
Oligodendrocyte progenitors arise from the neuroectoderm in the subventricular 
zone, then migrate and differentiate into mature myelin-forming cells.
Considering the fact that these processes occur at specific times, a number of cell 
specific markers have been used to divide the lineage into distinct phenotypic 
stages. These stages are pre-GD3 stage, pro-oligodendroblast stage, and immature 
oligodendrocyte stage (Pfeiffer et a l ,  1993). Certain mitogens such as PDGF 
(Miller et a l ,  1989) or FGF (McKinnon et a l,  1993), and IGF(McMorris et a l,  
1993) influence these cells, so they progressively change their morphology. It is 
obvious from in vivo and in vitro studies that neuronal influences play a critical role 
in oligodendrocyte differentiation, proliferation and survival (Barres and Raff, 
1993). In addition, thyroid hormone can regulate and promote early oligodendrocyte 
differentiation (Rodriguez-Pena, 1999). In contrast, retinoic acid (RA) has been 
found to inhibit oligodendrocyte differentiation as well as proliferation (Noll and 
Miller, 1994). The pattern of development and differentiation in tissue culture is 
thought to broadly mimic that in vivo.
1.4.3 Morphology
Light microscopy reveals only some aspects of oligodendrocyte morphology. The 
oligodendrocyte nuclei appear smaller, regular and more chromophilic than 
astrocyte nuclei (Peters et a l ,  1976). On the basis of ultrastructural morphology, 
three subtypes of differentiated oligodendrocytes have been defined in white matter, 
consisting of light, medium, and dark cells (Mori and Leblond, 1970). In general, 
oligodendrocytes possess a well developed rough endoplasmic reticulum (RER) 
and free ribosomes together with prominent Golgi apparatus. Microtubules are also 
a prominent feature. The electron density of the cytoplasm increases with maturity 
while the prominence and complexity of the cell’s processes decreases as active 
myelination abates.
1.4.4 Oligodendrocyte markers
The establishment o f antigenic cell type-specific surface markers facilitates the 
recognition of differentiated cells at different developmental stages. In other words, 
undifferentiated progenitor cells give rise to oligodendroblasts, which mature into 
oligodendrocytes and they begin a sequential expression of specific antigens, which 
are later inserted into myelin membranes at different times and rates.
Rapidly dividing progenitor cells stain positively by a variety of antibodies such as 
A2B5 (Raff et ah, 1983) and undergo differentiation in vitro into oligodendrocytes 
or astrocytes, depending on the medium. As these early progenitors mature, they 
become 04+  cells (Sommer and Schachner, 1981) and divide more slowly (Dubois- 
Dalcq, 1987). Before these progenitors acquire galactocerebroside (GC) and 
sulphatide (Bansal et a l ,  1992; Berry et a l ,  1992) they express coincidently 0 4  and 
proligodendroblast antigen (POA) that binds to an antibody A 0 0 7  (Bansal et a l,
1992). At this stage of development, oligodendrocytes express certain antigens for 
instance sulphatide and seminolipids (Bansal et a l ,  1992).
The antigenic definition of an oligodendrocyte is the expression of GC (Raff et a l ,
1983). The traditional view, based largely on tissue culture is that expression of 
CNP appears concurrently with GC (Knapp et a l ,  1988) followed by myelin- 
associated glycoprotein (MAG) as well as myelin basic protein (MBP) and one or 
two days later by PLP (Knapp et a l ,  1987). However, more recent in vivo studies 
show that both CNP and the DM20 isoform of PLP are present in progenitors, prior 
to GC expression (Scherer et a l ,  1994; Dickinson et a l ,  1996; Spassky et a l,
1998).
In cultured cells diffusely distributed MBP can be seen throughout the cell bodies 
and processes (Dubois-Dalcq et a l ,  1986; Konola et a l ,  1991). A week later, fine 
grains of MBP staining are seen also in sheets surrounded hy loops of processes 
(Dubois-Dalcq et a l ,  1986; Konola et a l, 1991). MAG is confined to the 
perinuclear cytoplasm initially (Dubois-Dalcq et a l ,  1986). PLP is initially present 
in the perinuclear region as gianular shaped deposits (Dubois-Dalcq et a l,  1986; 
Konola et a l ,  1991). By two weeks it is detectable in the processes (Dubois-Dalcq 
et a l ,  1986; Konola et a l ,  1991). Moreover, MBP and PLP are differentially 
located; MBP is present in membranous sheets of mature oligodendrocytes whereas 
PLP/DM20 is mainly detected along the course o f the cell processes (Konola et a l ,  
1991). Finally, CNP is mainly located in the networks of processes and in the 
periphery of sheets (Knapp et a l ,  1987; Konola et a l,  1991). O f the “O” group of 
antibodies, the CIO and O il  define the most mature oligodendrocytes (Kuhlmann- 
Krieg et a l ,  1988). Strikingly, the “O” group of antibodies (Kuhlmann-Krieg et a l.
1988) is consistent with the electron microscopic study regarding light to medium 
oligodendrocytes (Mori and Leblond, 1970). Stages of oligodendrocyte 
development and differentiation are shown in (Figure 1, page 22).
1.4.5 Myelination
Myelination commences at appropriate times of development in different regions of 
the nervous system. The initiation of myelination, however, commences just before 
birth in the mouse and is completed postnatally. During myelination, 
oligodendrocytes, the myelinogenic cells o f the CNS, elaborate numerous processes 
that extend to reach axons and begin to ensheath in spiral patterns (Hahn et al., 
1987). It has been noted that myelination first starts at cervical levels of the spinal 
cord and subsequently extends in a rostrocaudal direction, as well as in a caudal to 
rostral direction through the brain (Schwab and Schnell, 1989). In general, 
myelination occurs in the ventral regions of the spinal cord and brain before the 
more dorsal regions. Even within regions there may be considerable differences in 
the timing of myelination; for example, between the fasciculus gracilis and the 
fasciculus cuneatus.
A heterogeneous population of white matter oligodendrocytes has been described, 
ranging from those that myelinate a single large diameter axon in a fashion similar 
to Schwann cells in PNS (type IV) to those ensheathing multiple small diameter 
fibres (types I & II) (Del Rio Hortega, 1921; Remahl and Hildebrand, 1990). Type 
III cells myelinate only a few large diameter axons. Oligodendrocytes, therefore, 
can be classified into at least two distinct subpopulations accordingly to the number 
and diameter of fibres they support (Butt et ah, 1995). Molecular differences also 
exist between oligodendrocyte populations; for example with transferrin (Espinosa 
de los Monteros and Vellis, 1990), carbonic anhydrase II (Butt et a l ,  1995) and 
small MAG (S-MAG) (Butt et a l ,  1998). Surprisingly, it has been reported in 
higher vertebrates that heparan sulphate proteoglycans (HSPGs) may define the 
myelinogenic phenotype of oligodendrocyte populations (Szuchet et a l ,  2000). 
During the active stages of myelination, immunocytochemistry has revealed that 
MBP appears prior to PLP. Moreover, large diameter fibres have higher MBP and 
less PLP than small diameter fibres and, vice versa (Hartman et a l ,  1982). It could 
be concluded that molecular structure of myelin does not play a critical role in 
determining axonal sizes (Norton and Gammer, 1984). Nonetheless, a more recent 
report using transplantation supports the idea that each oligodendrocyte has the 
inherent potential to myelinate any calibre of axon (Fanarraga et a l ,  1998).
1.4.6 Adult oligodendrocyte progenitors
The greatest number o f oligodendrocyte progenitor cells exists during the period of 
normal myelination in the perinatal period. Such cells have been termed perinatal 
progenitors and, when cultured, were often referred to as oligodendrocyte-type 2 
astrocyte (0-2A) progenitors (see 1.7, page 7). The presence of progenitors in the 
adult CNS is now established. They were originally identified in culture and 
exhibited some differences from their perinatal counterparts, such as longer cell 
cycle times and lower migratory capacity (Wolswijk and Noble, 1989; Wolswijk et 
a l,  1990; Wren et a l ,  1992). More recently, NG2 has been used to identify the 
adult progenitor cells in vivo and the use of this marker has revealed a highly 
developed network of such cells (Nishiyama et a l ,  1999).
Although not directly concerned with the work in this thesis, a highly topical area 
concerns the presence of adult neural stem cells which can be isolated and driven to 
differentiate into neurons and glia (Frisén et a l ,  1998; Bjomson et a l,  1999; 
Doetsch et a l ,  1999; Laywell et a l ,  2000). In fact, under some circumstances the 
oligodendrocyte precursors can be induced to revert to multipotential stem cells 
(Kondo and Raff, 2000).
1.5 The astrocytes
Morphologically, there are two classical types of astrocytes, protoplasmic and 
fibrous, the later being more abundant in CNS white matter. However, using a 
variety of molecular criteria it is evident that there is marked inter- and intraregional 
heterogeneity of astrocytes. It is generally accepted that within the CNS glial 
fibrillary acidic protein (GFAP) is a specific marker for astrocytes in health and 
disease states (Bignami et a l ,  1972). Astrocytes extend processes to the surface of 
the CNS and to the perivascular space forming a glial limiting sheath (Meier and 
Bischoff, 1975; Miller and Raff, 1984) and to nodes of Ranvier (ffrench-Constant et 
a l,  1986). Although originally thought of as having purely a structural role, it is 
now evident that astrocytes have a complex functional inter-relationship with 
neurons and oligodendrocytes. Ascribed functions include maintenance of ion 
homeostasis, uptake and recycling of neurotransmitters, modulation of synaptic 
activity, synthesis and release o f neurotransmitters and propagation of calcium 
waves (Bezzi and Volterra, 2001). The proposed functions are indicative of the 
importance of astiocytes in the CNS.
Astrocytes are also able to secrete factors, such as PDGF-A, bFGF and IGF-1 that 
promote oligodendrocyte mitosis, migration and survival (Bhat and Pfeiffer, 1986; 
McMorris and Dubois-Dalcq, 1988; Richardson et a l ,  1988; Noble et a l,  1988;
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to axons (Meyer-Franke et a l ,  1999).
1.6 The microglia
The microglia are the resident macrophages of the CNS. They colonise the CNS 
early in development, originating from the yolk sac (Alliot et a l ,  1999). The 
resident microglial population is renewed from the circulating pool of monocytes. 
In normal CNS development, they play important roles, thereby eliminating debris 
(Perry and Gordon, 1988; Stoll and Jander, 1999). The density of microglia is 
higher in the neonate declining after birth and then increasing again in older 
animals. Following disease or injury there is a rapid increase in 
microglia/macrophage cells due to proliferation of endogenous cells and recruitment 
of circulating cells. The contribution played by circulating cells varies with different 
insults. Microglia display surface antigens common with vascular system 
macrophages.
1.7 Oligodendrocyte type-2 astrocyte
The 0-2A progenitors derived their name from the their ability to differentiate into 
oligodendrocytes or type 2 astrocytes, depending on the tissue culture medium. They 
appear however, to be a peculiarity of in vitro situations and, with a few exceptions in 
experimental studies, are not found in vivo. As they are not relevant to the thesis, they will 
not be discussed further.
1.8 The axon
The axons are unique processes, which project from neurones. They have relatively 
few organelles compared with the soma or dendrites and lack a Golgi apparatus and 
rough endoplasmic reticulum. The axon consists of the cytoskeleton and axoplasm 
surrounded by the axolemma (Peters et a l,  1976). The neurofilaments and 
microtubules form the main components of the cytoskeleton but there is also a well- 
developed microtubular network and numerous interlinking molecules, such as 
spectrin. Membranous structures include mitochondria, the axoplasmic reticulum 
(which is an extension of the smooth ER of the cell body), vesicles and various 
endosomal components. The axon and its axolemma show considerable regional 
specialisation at the nodes, paranodes, juxtaparanodes and the intemode, which 
forms the greatest part of the axon’s length.
The axon has two main functions, the propagation of impulses and the transport of 
materials in both retrograde or anterograde directions (Hirokawa, 1993). Impulse 
conduction initiates in the initial axon and, in myelinated axons, progresses in a 
salutatory manner. This form of conduction is dependent on the ion channel 
specification at nodes and adjacent paranodes/juxtaparanodes. In unmyelinated and 
dysmyelinated or demyelinated axons, conduction is continuous in keeping with the 
more even and continuous distribution of ion channels.
1.9 The axoglial Interaction
There is an intimate relationship between the axon and its associated 
oligodendrocyte in which the development and well-being of each depends critically 
upon the other. During development axons influence the proliferation, 
differentiation and survival of oligodendrocyte lineage cells (Barres and Raff, 1993; 
Barres and Raff, 1994; Barres and Raff, 1999). Several growth factors, such as 
PDGF-A and neuregulin, which are derived from axons, promote mitosis and/or cell 
survival (Yeh et a l ,  1991; Canoll et a l ,  1996; Flores et a l ,  2000). Electrical 
activity of axons is also proposed to influence oligodendrocyte mitosis and 
myelination (Barres and Raff, 1993; Demerens et a l ,  1996; Zalc and Fields, 2000). 
Axons guide migration of neurons and glia (Leber and Sanes, 1995) and may also 
secrete factors, such as jagged, that inhibit oligodendrocyte differentiation (Wang et 
a l ,  1998) through notch activation. Axons influence the expression of myelin genes 
in oligodendrocytes (McPhilemy et a l ,  1990; Kidd et a l ,  1990; McPhilemy et a l ,
1991) and have been recognised for many years as necessary for the maintenance of 
the myelin sheath.
The role o f oligodendrocytes in promoting the differentiation of the axolemma has 
been known for over 20 years (Bray et a l ,  1981; Oldfield and Bray, 1982). 
Recently some of the molecular mechanisms have become clearer. The organisation 
of axolemmal molecules at the node, paranode and juxtaparanode depends on both 
secreted factors and myelination (Kaplan et a l,  1997; Rasband et a l ,  1999a; 
Rasband et a l ,  1999b; Popko, 2000; Trapp and Kidd, 2000; Tait et a l ,  2000; 
Kaplan et a l ,  2001; Pedraza et a l ,  2001). In some instances the specific 
oligodendrocyte molecules have been identified that are critical for the correct 
organisation of the axolemma. For example, absence of GC, the major glycolipid, 
results in absence of the transverse bands and a redistribution of contactin and Kv 
channels along the intemode (Dupree et a l ,  1998a; Dupree et a l ,  1998b; Popko, 
2000).
Oligodendrocytes also influence the formation of the cytoskeleton and axonal 
transport. The neurofllaments and microtubule composition and their 
phosphorylation status and hence the axonal diameter is dependent upon the 
oligodendrocyte, although there is some debate as to whether myelin formation per 
se is necessary (Sanchez et a l ,  1996; Brady et a l ,  1999; Witt and Brady, 2000; 
Sanchez et a l ,  2000; Kirkpatrick et a l ,  2001). One interesting aspect relevant to 
this thesis is the role that myelin mutants have played in elaborating some of the 
above hypotheses.
1.10 Myelin sheath
Two highly specific glial cells, the oligodendrocytes in the CNS, and the Schwann 
cells in the PNS, are responsible for the formation of compact myelin. The mature 
myelin-forming cell processes rotate around axons making up successively spiral 
layers from which the cytoplasm is extruded to form the compact sheath. 
Structurally, the myelin sheath is made up of a phospholipid hilayer that contains 
intrinsic and extrinsic proteins.
When viewed by conventional transmission electron microscopy, the myelin sheath 
shows a pattern of dark and lighter bands at a regular periodicity of approximately 
1 him  (This varies according to fixation and the thickness of the myelin sheath). The 
thicker, darker line is the major dense line (MDL) formed by fusion of the 
cytoplasmic surfaces of the oligodendrocyte processes. The less electron dense line 
is actually a double line, separated by a 2-3nm gap and is the intraperiod line (IPL). 
This is formed by the close apposition of the extracellular surfaces of adjacent 
lamellae. The thickness of sheath varies in relation to the axonal calibre. It is not 
unusual to have small regions of uncompacted processes within a compact sheath; 
while this is common in developing animals it may also be seen in mature mice.
1.11 LIpId composition In myelin
The lipid component is a major constituent making up about two thirds o f solid 
matter of myelin (Norton and Cammer, 1984). It comprises galactosphingolipids 
including GC and sulphatides, cholesterol, and plasmalogen (Hildebrand et a l,
1993). These lipids are also not restricted to myelin. Within the CNS, GC is unique 
to oligodendrocytes, which makes it an excellent surface marker for these cells 
(R siïîe ta l,  1978).
Although myelin has minor galactolipids, half of which consist o f several fatty acid 
esters of cerebroside, and the other half of two glycerol-hased lipids,
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diacylglycerylglacoside, called collectively glacosyldiglyceride. The biosynthesis of 
these glycerol derivatives is coincidentally related to myelination (Norton and 
Cammer, 1984). Myelin also contains a little phosphatidylinositol that binds tightly 
to myelin proteins. Ethanolamine phosphoglyceride, the most abundant 
phospholipid, is located exclusively in the inner half of the bilayer. Moreover, the 
non-significant myelin lipids include di-and tri-phosphoinositide, a series of fatty 
acid esters o f cerebroside, at least three galactosyldiglyceride derivatives, a series of 
gangliosides and some alkanes.
1.12 Myelin proteins
1.12.1 Myelin-associated glycoprotein (MAG)
MAG, the major myelin glycoprotein, belongs to the immunoglobulin gene 
superfamily. It constitutes 1% of the total myelin protein in both central and 
peripheral nervous system (Quarles et a l ,  1992). MAG has two developmentally- 
regulated isoforms of relative molecular mass 72 and 67 IcDa, Icnown as large and 
small MAG (L-MAG, S-MAG). The Mag gene expression is earlier in development 
than the major myelin protein genes, Pip and Mbp. Surprisingly, the MAG protein 
is absent in the compact myelin sheath but localises to the periaxonal space, 
paranodes and mesaxons in the CNS (Trapp and Quarles, 1984); and, additionally, 
Schmidt-Lanterman incisures in PNS. The functions that have been proposed for 
MAG include the adhesion of the myelin membrane with axon (Trapp and Quarles,
1984) and maintaining the periaxonal cytoplasmic collar o f the inner Schwann cell 
and oligodendrocyte. MAG has also been proposed to act as a signal transducer 
between axon and glial cells through an interaction with an, as yet unidentified, 
sialoprotein (Tang et a l ,  1997; Strenge et a l ,  1998). Recently, MAP IB has been 
identified as an axonal binding partner for MAG (Franzen et a l,  2001). MAG is 
also relevant to axonal regeneration, having a repellent activity in the adult CNS 
(Qiu et a l ,  2000). Surprisingly MAG null mutations show a minimal phenotype 
with only subtle changes in the periaxonal space and occasional double myelin 
sheaths in the CNS (Li et a l ,  1994; Montag et a l,  1994).
1.12.2 2 ,3 -cyclic nucleotide 3'-phosphodiesterase (CNP)
Two isoforms (46 and 48 kDa) have been reported for the enzyme CNP that 
catalyse the hydrolysis of several 2 ,3 -cyclic nucleoside monophosphates. They 
represent about 5% of the total myelin proteins (Lemke, 1988; Kurihara et a l,
1992). In CNS, CNP is localised in the oligodendrocyte plasma membrane and non­
compacted parts of myelin sheath such as paranodal loops, adaxonal cytoplasm.
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outer tongue processes and Schmidt-Lanterman incisures (Trapp et a l ,  1988). These 
proteins are expressed at an early stage o f development (Trapp, 1990), suggesting a 
role for CNP in myelination and myelin maintenance together with stabilising 
membrane components, although currently no precise function has been ascribed.
1.12.3 Myelin basic protein (MBP)
MBP denotes several differentially spliced isoforms having slightly different low 
molecular weights (14, 17.5, 18 and 21.5kDa) (Norton and Cammer, 1984; Ferra et 
a l,  1985; Aruga et a l ,  1991). MBP isoforms, which account for 30% of the total 
myelin proteins, are hydrophilic, extrinsic membrane proteins with isoelectric points 
at 10.5. During myelination, Mbp gene expression occurs early among the other 
myelin genes in CNS (Kanfer et a l ,  1989). In the CNS, antibodies stain specifically 
the compact myelin (Sternberger et a l ,  1978; Hartman et a l ,  1982). In contrast to 
MAG and PLP, MBP is localised mainly at the major dense line (MDL) o f the 
compact myelin (Omlin et a l ,  1982). The role of MBP in maintaining the MDL 
(Omlin et a l ,  1982; Readhead et a l ,  1987) is seen obviously in Mbp mutant 
shiverer mice in which the cytoplasmic surfaces o f the lamellae fail to fuse, forming 
a double MDL. Furthermore, MBP is critical for elaboration o f normal amounts of 
myelin as in its absence only small numbers of thin sheaths are formed.
1.12.4 Other CNS myelin proteins
Other proteins have been characterised and many, no doubt, are still to be defined. 
Examples of such proteins are myelin-oligodendrocyte glycoprotein (MOG) 
(Linington et a l ,  1984), myelin-oligodendrocyte-specific protein (MOSP) (Dyer,
1993), myelin-associated oligodendrocytic basic protein (MOBP) (Yamamoto et a l ,
1994) (Montague et a l ,  1997), oligodendrocyte-myelin glycoprotein (OMGP) 
(Mikol et a l ,  1993) and oligodendrocyte specific protein (OSP), also known as 
claudin-11 (Bronstein et a l ,  1996; Morita et a l ,  1999; Gow et a l ,  1999).
1.12.5 Theproteolipidprotein gene: structure and function
1.12.5,1 Chromosomal locus of PLP/DM20 gene
The single copy PLP gene maps on the X-chromosome (at Xq21.33-22 in man) 
(Willard and Riordan, 1985; Mattel et a l ,  1986). This critical gene encodes the two 
classical integral membrane protein isoforms, PLP and DM20.
The murine Pip gene is defined by a DNA region approximately 17 kb in length 
which constitutes seven, possibly eight, exons and seven introns (Macklin et a l ,  
1987; Bongarzone et a l ,  1999) (Figure 2, page 23). It also contains two
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transcription units (Macklin et a l ,  1987; Bongarzone et a l ,  1999). Moreover, the 
Pip gene primary transcript is alternatively spliced to produce PLP and DM20 and 
the recently described somal-restricted isoforms (srPLP and srDM20) (Bongarzone 
et a l ,  1999; Bongarzone et a l ,  2001). “Classical” PLP is 30kDa and DM20 is 
26kDa. The Pip gene demonstrates heterogeneity at the 5' non-coding region of the 
transcription unit (Milner et a l ,  1985; Macklin et a l ,  1987) and also uses three 
alternative polyadenylation sites thus generating different message sizes (Milner et 
a l,  1985; Gardinier et a l ,  1986; Macklin et a l ,  1987). Heterogeneity o f the 
transcripts as a matter of function is obscure. However, tissue specific expression 
would be the possibility for the multiple mRNAs.
1,12,5,2 Expression of P/p gene
Given the possibility for selective transcripts, it is interesting to compare spatio- 
temporal expression between Pip and Dm20. As early as embryonic day 10 (ElO) 
Dm20 mRNA is expressed in murine CNS whereas Pip mRNA is not detectable at 
this stage o f development. By approximately birth, Pip transcripts are detectable, 
correlating with the onset of myelination (Verity and Campagnoni, 1988). At the 
stage of most active myelination the Pip isoform expression is reaching its peak 
(Verity and Campagnoni, 1988). Furthermore, Pip and Dm20 mRNAs are 
concentrated in the oligodendrocyte cell body and expressed at relatively high levels 
even in the mature CNS (Amur-Umarjee et a l ,  1990). The DM20 protein can be 
recognised at approximately E l2 (Dickinson et a l ,  1996) in the mouse spinal cord 
in cells having characteristics of oligodendrocyte progenitors. The PLP protein is 
localised in the compact myelin in adult CNS.
The Pip gene is expressed in a diverse array of tissues throughout development, 
rather than solely in the oligodendroglial lineage. For example, DM20 is present in 
both myelinating and non-myelinating Schwann cells where it is localised to 
cytoplasmic regions and is not generally seen in PNS myelin (Griffiths et a l ,  1995). 
In addition, DM20 is detectable in the perineuronal satellite cells of spinal cord, 
cranial and autonomic ganglia, and in the ensheathing cells of the olfactory nerve 
layer of the olfactory bulb (Dickinson et a l ,  1997). The C6 glioblastoma line (Nave 
and Lemke, 1991) as well as cardiac myocytes express the endogenous Pip gene 
(Campagnoni et a l ,  1992). The significance of the Pip gene expression in the non­
myelinating cells is not clear but its expression during gestation leads to the 
suggestion that the Pip gene may have a role in development.
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1.12.5.3 Transcriptional control of Pip gene
Like other cellular and viral genes, Pip gene is transcribed by RNA polymerase II. 
The mRNAs encoding PLP are highly abundant in adult CNS and Pip gene 
regulation occurs predominantly at the level of transcription (Cook et a l ,  1992). Pip 
gene modulation occurs in different ways including adjustment of Plp:Dm20 
mRNA ratio, stabilisation o f mRNA, the turnover of mRNA, protein translation and 
degradation, and post-translation modification (Cambi and Kamholz, 1994). 
Analysis o f the 5' region o f the Pip gene has demonstrated multiple cis regions 
capable of binding trans factors (Hudson et a l,  1996; Wegner, 2000).
Regulatory elements in the 5' non-coding region and possibly intron 1 of the Pip 
transcription unit contain positive and negative cis-acting elements that are 
recognised by trans-acting factors (Wight and Dobretsova, 1997; Dobretsova and 
Wight, 1999; Dobretsova et a l ,  2000). There is speculation that the Pip gene 
promoter modulates tissue specific expression (Nave and Lemke, 1991; Cambi and 
Kamholz, 1994).
Additional factors have been proposed to act either positively or negatively on Pip 
gene transcription. However, the presence of a thyi'oid hormone response element 
located in the 5' region and exon 1 suggests transcriptional and post-transcriptional 
control (Gao et a l ,  1997). Retinoic acid has also been shown to increase mRNA 
half-life (Zhu et a l ,  1994). Unusually, steroids influence gene expression negatively 
in vivo (Tsuneishi et a l ,  1991) and positively in vitro (Zhu et a l ,  1994). 
Components of the nervous system such as axons induce signals that regulate 
expression of the Pip gene (Kidd et a l ,  1990; Scherer et a l ,  1992).
1.12.5.4 Post-transcriptional control
Use of two alternate splice sites, one internally in exon 3 and the other at the 3' 
exon/intron boundary, generates Dm20 and Pip mRNAs, respectively from the 
primary transcript. Dm20 mRNA differs from the Pip mRNA only by deletion of 
115 nucleotides that comprise exon 3B. Both sites display highly sequence 
similarities with U1 small nuclear ribonucleoproteins (UlsnRNP) that form an RNA 
duplex with the 5' splice site, an early regulatory event in the formation of the 
spliceosomes (Montague and Griffiths, 1997). A selectively functional site is 
recognised according to the relative and absolute amounts of SR proteins, possibly 
contributing to the cell specificity (Zahler and Roth, 1995). During early 
development in the murine embryo, Dm20 mRNA is expressed predominantly 
although its significance at this stage is unknown.
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1.12.5.5 Translation and post-translational modification
The Pip and Dm20 mRNAs are translated on the RER and the proteins delivered 
through the secretory pathway via the Golgi apparatus, cytoplasmic vesicles, to the 
final destination, the plasma membrane (Gow et a l ,  1994a), It has been suggested 
that developing oligodendrocytes reserve these proteins for a time prior 
incorporation into myelin sheath (Dubois-Dalcq et a l ,  1986). Furthermore, the 
trafficking mechanism is associated with the micro-tubular apparatus and is also in 
partnership with other myelin components (Brown et a l ,  1993).
Two post-translational modifications occur for PLP and Dm20; the deletion of the 
N-residue from both proteins (Milner et a l ,  1985) and subsequent acylation of the 
cysteine residues (Weimbs and Stoffel, 1992). Like many membrane proteins, PLP 
and DM20 have no cleaved amino terminal signal. Strikingly, the minor srPLP and 
srDm20 isoforms do have a cleaved sequence encoded by exon 1.1 (Bongarzone et 
a l ,  1999).
1.12.5.6 Topology of the PLP/DM20 protein
Despite other proposal models for the membrane topology of the PLP protein based 
on mathematical modelling, chemical labelling, limited protease digestion, and 
immunolabelling, the most generally accepted is the model proposed by Popot et 
al,  (1991) and Pham-Dinh et a l ,  (1991) (Figure 3, page 24). The PLP (but not 
DM20) protein isoform is an extremely hydrophobic and highly charged 
membranous protein in the CNS (Weimbs and Stoffel, 1992). It can thus be inferred 
that the DM20 protein may adjust a proper topological orientation to suit its 
function.
1.12.5.7 Conservation of the Pip gene
At least five mammalian species (mouse, rodent, dog, bovine, and human) display 
considerable amino acid sequence similarities of PLP. The similarity of amino acid 
sequences between human and rodent reaches 100% whereas in the dog it is 99% 
and in the bovine 97% (Milner et a l ,  1985; Macklin et a l ,  1987). Nonetheless, the 
sequence similarity moves to the non-coding and non-transcribed regions of the Pip 
gene. There is approximately 93% and 86 % similarities in the 5'-UTR and 3'-UTR, 
respectively, between human and rodent (Roth et a l ,  1986). Again, human and 
rodent show highly conserved regions at the cap sites of the 5'-UTR (Macklin et a l,  
1987). Recently, it has been shown that the similarity extends to the 5' flanking 
sequence of the Pip gene (Montague and Griffiths, 1997). An extreme conservation 
of amino acid sequence (see above) suggests a very strong association between the 
primary structure and the function of the PLP.
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1.12.5.8 The DM  gene family
Based on the sequence similarities, other members of the so-called D M  gene family 
have been identified in mammals and lower organisms. Two membrane proteins 
termed M6a and M6b (Yan et a i,  1993), are expressed in the CNS, the former being 
restricted to neurons (Yan et a l,  1996) and Muller glial cells (Mi et a l, 1998). M6a 
is also expressed in non-neural tissues such as apical surface of choroid plexus, 
renal tubules and olfactory epithelium. M6b is expressed in oligodendrocytes and 
neurons (Yan et a l ,  1996). Both M6a and M6b are glycoprotein in nature. 
Moreover, three DM20-like molecules termed DM a, DMp, and DMy have been 
identified in shark and high similarities are noted between D M a and mammalian 
DM20 (Kitagawa et a l ,  1993). D M a and DMy are expressed in myelinated tracts of 
shark CNS. M6a is closely similar to DMp.
1.12.5.9 Proposed functions of the Pip gene
The well-defined functions o f PLP and DM20 are only partly resolved. The 
proposed functions have been derived largely from study of Pip gene mutants 
showing hypomyelination and abnormal periodicity, and, more recently, from gene 
loiockouts. In both Pip null animals and those with missense mutations there are 
abnormalities of the IPL, This feature, therefore, suggests a structural role for PLP 
in maintaining the IPL of the compact myelin (Duncan et a l,  1987; Boison and 
Stoffel, 1994; Boison et a l, 1995; Rosenbluth et a l ,  1996; Klugmann et a l ,  1997; 
Yool et a l ,  2002). Additionally, the formation of homophilic or heterophilic 
interaction between PLP and DM20 proteins at the extracellular regions of the 
molecules may possibly reflect adhesive peculiarities (Sinoway et a l, 1994).
The expression of Dm20 mRNA early in development in the CNS and non-neural 
tissues suggests other functions for the Pip gene products apart from the structural 
role (Timsit et a l, 1992). Spontaneous mutations of the Pip gene result in increased 
numbers o f dead oligodendrocytes (Knapp, 1996), leading to the suggestion that the 
Pip gene may be involved in the regulation of glial development and differentiation. 
In vitro studies demonstrate that a released Pip gene product may act as a mitotic 
factor that increases astrocyte and oligodendrocyte numbers (Yamada et a l, 1999). 
However, Pip null mice appear to have normal numbers of oligodendrocytes (Yool 
et a l, 2001). There is also a suggestion that PLP and DM20 may form pores in the 
membrane that act as proton translocation units (Helynck et a l, 1983). The DM  
gene family show high similarities to documented receptor proteins, strengthening 
the possibility for their role in permeability of the myelin membrane (Kitagawa et 
a l, 1993).
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More recent studies in PLP-deficient mice and humans suggests a role for 
PLP/DM20 in oligodendrocyte/axon inter-relationships. In the absence of these 
oligodendrocyte proteins, axons develop multiple swellings, possibly reflecting 
defects in axonal transport. There is also a late-onset degeneration of the distal 
regions of long axons such as those in the fasciculus gracilis and corticospinal tracts 
(Griffiths et ah, 1998; Garbern et a l ,  2002).
1.12.5.10 Pip gene mutations and disease
A range of species (mouse, rat, rabbit, dog, and human) display myelin defects as a 
result of spontaneous mutations of the Plp/PLP gene.
1.12.5.11 PLP  gene-related disorders in man
Pelizaeus-Merzbacher Disease (PMD) and X-Linked Spastic Paraplegia Type 2 
(SPG2) are two human syndromes caused by various mutations or dosage changes 
of the PLP  gene.
1.12.5.12 Pelizaeus-Merzbacher Disease (PMD)
Pelizaeus and Merzbacher first described PMD in 1885 and 1910, respectively. The 
proposed classification of the disease into three forms is based on familial and 
unfamilial PMD, together with the severity. These are classical (type I), connatal or 
congenital (type II) and transitional forms (type III) (Seitelberger et a l, 1996). 
Clinically, the disease shows devastating symptoms and signs include nystagmus, 
delayed psychomotor development, spasticity, cerebellar ataxia, optic atrophy, 
laryngeal stridor, seizures, and mental retardation that often results in premature 
death of the patients (Hodes et a l,  1993; Seitelberger, 1995). The neuropathological 
criteria in PMD consist of hypomyelination of CNS especially in areas that 
myelinate relatively late, for instance the cerebellar and cerebral parts. The 
hypomyelination may be diffusely generalised or show a “tigroid” appearance 
where small islands of myelin are present. Oligodendroglial cells are reduced in 
number while astrocytes are markedly increased. In contrast to males, who mainly 
contract the disease, females are only sporadically affected by clinical PMD.
1.12.5.13 X-Linked Spastic Paraplegia Type 2 (SPG2)
SPG 2 is allelic to PMD. It is defined as a rare disorder that can be clinically 
classified into the pure form and the complicated form. In patients with the pure 
form, spasticity of the lower limbs is the dominant feature whereas other signs such 
as cerebellar ataxia, sensory loss, nystagmus, optic atrophy and mental retardation 
are present in the complicated form. Both PMD and SPG2 share similarities and
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there is considerable overlap. Females from affected families act as asymptomatic 
carriers (Saugier-Veber et a l, 1994). The lesions of the disease are confined mainly 
to the CNS white matter, especially the long spinal tracts which are critically 
affected (Seitelberger, 1995).
In general, mutations of the PLP gene rarely affect the PNS. However, peripheral 
neuropathy has been documented in patients with null mutations of the PLP  gene 
(Garbern et a l,  1997).
1.12.5.14 Molecular genetic basis of PLP  gene mutations in humans
Genetic mechanisms may govern the severity of the disease phenotypes in many 
ways. The majority of patients with PMD/SPG2 have a duplication of a region of 
the X chromosome containing the PLP  locus (Harding et a l ,  1995; Hodes and 
Dlouhy, 1996; Sistermans et a l ,  1996; Sistermans et a l ,  1998). There is variation of 
the size and position of the duplicated region (Woodward et a l,  1999; Woodward et 
a l,  2000; Hodes et a l,  2000) which may account, at least in part, for the variability 
in phenotype.
Point mutations in the PLP  gene mutations account for the majority o f remaining 
PMD and SPG2 patients (Hudson et a l ,  1989; Trofatter et a l, 1989; Gencic et a l,
1989). Genetic heterogeneity of PMD among patients is clearly noted with different 
families displaying a variety o f point mutations leading to different amino acid 
substitutions (Trofatter et a l,  1989). Most o f these point mutations are confined to 
the coding regions of the PLP  gene; however, other mutations in non-coding 
regions are also reported. It has been suggested that some PMD families may have 
mutations in non-transcribed regulatory regions (Cambi et a l ,  1996; Inoue et a l,
1997). Some of these mutations result in protein truncation or aberrant splicing or 
even conservative amino acid substitution that have little effect on protein 
conformation. The PLP protein seems to be intolerant to structural changes. The 
high conservation of the wild type PLP protein suggests a mechanism for protein- 
protein interaction but in most mutants this relationship is potentially altered due to 
the change in the amino acid sequence.
Mild PMD phenotypes have also been reported resulting from PLP gene deletion 
(Raskind et a l,  1991; Osaka et a l ,  1996) or null mutations (Garbern et a l,  1997).
New mutations of the PLP  gene are being described frequently; an up to date 
database is maintained at;- http://www.med.wayne.edu/Neurology/plp.html
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1.12.5.15 Pip gene mutations in animals
Spontaneous mutations in the Pip gene are described in a wide range of species that 
includes mouse, rat, dog, and rabbit (Figure 4,page 25). In the jim py  ( P ^ )  mouse, 
a mutation at the 3^  splice site of intron 4 leads to the deletion of exon 5 from the 
Pip gene final transcript (Nave et a l ,  1987; Hudson et a l,  1987). Unlike the jim py  
mouse, various point mutations result in amino acid substitutions in jimpy-4j (Plp’^ ' 
^^ ) (Pearsall et al., 1997), myelin synthesis deficient (Gencic and Hudson,
1990), and rumpshaker {Plp’^ '''^ ^^ ) mice (Schneider et a i ,  1992), the myelin deficient 
rat (Boison and Stoffel, 1989), shaking pup  (Nadon et a l, 1990), and paralytic 
tremor rabbit (Tosic et a l,  1994).
Most mutants start to show obvious tremor between 10-12 days in mouse and the 
more severe phenotypes such as jim py  and the myelin deficient rat often seizure 
between 3 and 4 weeks of age and die prematurely at around P30. Exceptionally, the 
paralytic tremor rabbit and mild form of rumpshaker show less severe phenotypes 
and affected males are able to reproduce. As they age, both mutants show slight 
progression in myelination (Taraszewska, 1988; Tosic et a l,  1996). The interesting 
fact in the Pip gene mutants is that Schwann cells and the myelin sheaths are 
apparently normal.
1.12.5.16 Phenotypic characteristics of Pip gene mutations in animals
The common feature among these mutants is dysmyelination, which is characterised 
by hypomyelination and abnormal myelin. Many axons are naked or ensheathed 
only with one or two wraps of oligodendrocyte processes. Any myelin sheaths tend 
to be disproportionately thin for the calibre of axon. The severity o f the myelin 
deficit varies considerably between different mutations.
In mice, the most affected are the jim py  and jimpy-4j which develop a severely 
hypomyelinated phenotype (Sidman et a l,  1964; Vela et a l,  1998) with abnormally 
thin myelin sheaths (Ransom et a l,  1985; Billings-Gagliardi et a l,  1995; Duncan, 
1995) and poorly compacted, ultrastructurally-abnormal myelin (Duncan et a l,  
1987; Billings-Gagliardi et a l,  1995). The double IPL is completely fused to a 
single electron-dense structure. As a result the myelin periodicity decreased from 11 
nm in the wild type to 9 nm in the mutants (Duncan et a l,  1987).
Compared with jimpy, the mild form of rumpshaker is an example of moderate 
dysmyelination. As rumpshaker mice age, they show reduced tremor and an 
increased amount of myelin (Fanarraga et a l,  1992). A heterogeneous population of 
myelin sheaths is reported, some have normal periodicity and others have hised IPL 
(Griffiths et a l,  1990).
I V
Mutations in the Pip gene appear to affect the oligodendroglial lineage differently. 
Mutants such as jimpy, jimpy-4j, myelin synthesis deficient mice and myelin 
deficient rat show a severe reduction in the number of mature oligodendrocytes in 
older mice (Billings-Gagliardi et a l, 1995; Knapp, 1996). Strikingly, immature 
oligodendrocytes are not affected in these mutants (Ghandour and Skoff, 1988; 
Skoff, 1995; Nadon and Duncan, 1996; Gow et a l,  1998; Lipsitz et a l,  1998; 
Grinspan et a l,  1998). An increased glial cell proliferation has also been noted in 
jimpy, the myelin deficient rat and the shaking pup  (Knapp et a l, 1986; Jackson and 
Duncan, 1988; Duncan, 1990). There is no increased cell death recorded among the 
shaking pup  oligodendrocytes. However, these oligodendrocytes fail to mature and 
further myelinate the CNS (Nadon and Duncan, 1996). The premature death of 
oligodendrocytes is also suggested in jimpy  (Meier and Bischoff, 1975; Privât et a l, 
1982; Knapp et a l, 1986; Knapp et a l,  1990; Skoff and Knapp, 1990) and the 
myelin deficient rat (Jackson and Duncan, 1988; Boison and Stoffel, 1989). 
Oligodendrocyte numbers are normal in the paralytic tremor rabbit and the mild 
form of rumpshaker (Griffiths et a l, 1990; Schneider et a l ,  1992).
Distension of the RER is clearly seen in the shaking pup  and the myelin deficient rat 
(Dentinger et a l, 1982; Duncan et a l, 1983; Jackson and Duncan, 1988). Moreover, 
a moderate swollen rough endoplasmic reticulum has been reported in 
oligodendrocytes o f the myelin synthesis deficient mice (Billings-Gagliardi et a l, 
1983). Using immunocytochemistry, the RER, but not the Golgi apparatus or cell 
surface, is positively stained for PLP/DM20 (Roussel et a l,  1987; Gow et a l,
1998). It could be concluded that the transport of PLP/DM20 is altered and may be 
the result o f misfolding (Jung et a l, 1996). The absence of swollen RER, in 
particular in jimpy, suggests a quick turnover of misfolded proteins. DM20 protein 
levels are maintained in both rumpshaker and paralytic tremor rabbit compared 
with control and the protein is successively incorporated into myelin sheath 
(Griffiths et a l, 1990; Mitchell et a l ,  1992; Karthigasan et a l ,  1996). However, a 
little mutated PLP is accumulated in the RER in the rabbit mutant (Karthigasan et 
a l,  1996).
The severity of astrocytosis (Billings-Gagliardi et a l,  1995; Duncan, 1995) also 
varies between mutants.
1,12.5.17 Female carriers of Pip gene mutations
Males are usually affected by X-linked diseases whereas females, bearing the 
affected allele, seldom show the disease phenotype. The X-chromosome 
inactivation, which is a normal event in each somatic cell, occurs in females. For 
instance, female mice heterozygous for the jimpy  gene show a mosaic population.
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some of oligodendrocytes express the wild type Pip allele and the others express the 
jim py  allele. This could explain the premature death of some oligodendrocytes 
(Kagawa et a l ,  1994), while the cells that escape this fate form considerable myelin 
(Skoff and Ghandour, 1995). In addition, occasional patches of dysmyelination are 
also seen, which are more likely to be formed by oligodendrocytes bearing the jim py  
allele. The disappearance of dysmyelinating patches suggests a compensation role 
by oligodendrocytes carrying the wild type Pip allele (Bartlett and Skoff, 1986; 
Skoff and Ghandour, 1995). The early death of jim py  oligodendrocytes and 
processes o f compensation may have impact in controlling apparent clinical signs in 
female carriers (Belmont, 1996).
Amazingly, females with an affected allele can develop clinical phenotypes based 
on skewing o f X-inactivation phenomenon (Willard, 1995). In this context, females 
bearing the shaking pup allele may represent skewing of the X-inactivation since 
several phenotypes o f varying degree are observed (Cuddon et a l,  1998). The 
phenotype varies not only between different mutations of the Pip gene but also 
within heterozygotes for the same mutation. Dysmyelinated patches are seen 
frequently in the optic nerves of jim py  mice, myelin-deficient rat and shaking pup 
but only in the last mutant are spinal cord patches a regular feature.
Two phenotypes, juvenile-onset (Hodes et a l, 1995; Hodes et a l, 1997) and adult- 
onset (Nance et a l, 1996), are described in female carriers of PMD.
1.12.5,18 Pip null mice (gene knockout)
Null mice, lacking PLP and DM20, provide a useful model to test the normal 
cellular function of PLP. Two lines of mice have been generated using different 
targeting strategies (Boison and Stoffel, 1994; Klugmann et a l, 1997). Pip null 
mutants develop normally without any of the clinical signs of naturally occurring 
dysmyelinated mice, for example jimpy. Oligodendrocytes appear normal and 
produce thick myelin sheaths. However, the structure of the myelin sheath is 
abnormal with regions of “loose” myelin and areas of compacted myelin. 
Abnormally condensed IPL are noted in these mice (Rosenbluth et a l, 1996; 
Klugmann et a l, 1997) and also regions in which no IPL is evident (Yool et a l, 
2002). Demyelination is not detected, even at the age o f two years. Both PLP and 
DM20 appear unnecessary for oligodendrocyte survival and myelin formation; 
however the presence of these proteins does confer an advantage when Pip null 
oligodendrocytes are in competition with wild type cells (Yool et a l, 2001). Axonal 
swellings, containing mainly membranous organelles and mitochondria, are 
associated with small axons. The swellings are found from about P40 in the optic 
nerve. These swellings, therefore, suggest defects in axonal transport. Late-onset
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degeneration of long spinal tracts occurs from the age of about 8 months onward 
and exhibits a length-dependent progression (Griffiths et a l, 1997; Garbern et a l, 
2002). It has been speculated that the axonal swellings are specific to the absence of 
PLP/DM20 (Griffiths e ta l ,  1998).
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0-2A Perinatal progenitor cells
A2 B+ /Vi menti n+GD3 +
0-2A adult Progenitor ceils 
0 4 +/vimentin-GD3 +
Oligodendroblast
0 4 + /G a lc +
1
Adult oligodendrocyte
04+/G alc+/M B P+
Astrocyte type-2 
GFAP+/A2B5-f-/FGF-R3-
Fig. 1. Oligodendrocyte development and differentiation in the murine CNS (modified 
from Lee J. 0 . et al., 2000). 0 -2 A  cells develop into oligodendrocytes and astrocyte 
type-2. 0 -2 A  progenitors derive into either a differentiated progeny or different 
precursor cells present in the adult. The differentiation into adult oligodendrocytes is a 
process represented by expression of specific marker(s). Some of these markers are 
given beside each stage of differentiation.
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Fig. 4. Regions o f  point mutations in the animal PLP. A m ino acid transitions 
resulting in neurological disorders are highlighted green.
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2. Aims
Mutations of the PLP gene have heterogeneous phenotypes. The severity can range 
from early lethal forms of Pelizaeus-Merzbacher Disease to the mildly affected 
form “spastic paraplegia type 2”.
Likewise, the rumpshaker mutation on C3H/101 and C57BL/6NCrlBR backgrounds 
shows mild and severe phenotypes, respectively, which hopefully, provide an 
authentic model for PMD and SPG2. The focus of this study was to compare the 
phenotypes of rumpshaker on the two different genetic backgrounds. The approach 
work was designed to cover the life-span of the severe phenotype of the mutation, 
which is about 30 days. The mutant and the littermate control animals from both 
genetic backgrounds were investigated histopathologically at various ages to 
quantify various parameters linked to the development and the progression of the 
neurological manifestation. These included myelin status and behaviour of the glial 
population. Immunohistochemistry was used to confirm the results obtained from 
examining resin sections and finally, levels of selected myelin proteins and GFAP 
were quantified on Western blotting. Comparing the two mutants may provide new 
fundamental information that allows a better understanding of diverse phenotypes in 
PMD and SPG2.
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3. Material and methods
3.1.1 Mouse breeding and gene nomenclature
Mice were maintained at Glasgow Parasitology Unit and Veterinary Research 
Facility, University o f Glasgow Veterinary School. The mice were housed with free 
access to regular laboratory diet, at constant temperature and humidity, during the 
entire experiment. All experimentation reported in this thesis was conducted on 
neural tissues obtained from only male mice.
Two strains (C57BL/6NCrlBR (abbreviated to C57) and C3H/101 (abbreviated to 
C3H)) of mice were used for the current work. C57 mice were obtained from a 
colony maintained at Zentrum fur Molekulare Biologie (ZMBH), Universitat 
Heidelberg, Im Neuenheimer Feld 282, D-69120 Heidelberg, Germany and 
established from the original C3H rumpshaker mice which were discovered and 
maintained at Glasgow University Veterinary School. A genetic nomenclature of 
normal and some mutant alleles are illustrated in Table 1, page 27.
All studies were perfomed under licence from the Home Office (project # 60/2077).
Table 1. G enetic nom enclature o f norm al and m utant alleles
Alelle Gene symbol
wild type (WT) Pip
rumpshaker Plj^ p-<sh
rumpshaker male
rumpshaker heterozygote
rumpshaker homozygote
jimpy Plpi”
jim py  male PljJ^ly
jimpy  heterozygote PlfJ'’l+
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3.1.2 Rotarod
Mice were placed, facing the opposite direction to the operator, on the Rotarod 
(UGO BASILE) with the speed at rest. When the drive is activated, the rod slowly 
accelerates to reach the maximum speed (30rpm). At first the mice were given 2-3 
conditional trials to familiarise them with the rod and then four actual tests 
followed. After each task, the mice were rested for 10-15 minutes. The mean was 
calculated for the four readings.
3.1.3 GrowthAVeight of mice
After killing, the mice were immediately weighed and then perfused or dissected for 
fresh cryopreservation. The weight gain is, in general, an indicator of development.
The two basic factors responsible for the pattern of growth and adult size of animals 
are its inherited characteristics and the environment. Some of these factors may 
have significant effects on weight gain such as age, size of litter, etc.
3.1.4 5-bromo-2-deoxyuridine (BrdU) labelling
Mice were injected intraperitoneally with BrdU in 0,9% sterile saline (50 |ag/g of 
mouse body weight. Sigma) at midday. After one hour, the mice were sacrificed and 
then perfused or the neural tissues were deeply frozen for cryopreservation.
3.2 Isolation and quantification of nucleic acids
3.2.1 Tail biopsy
1 cm of the tip of the tail was removed from mice anaesthetised with halothane 
(Rhone-Poulenc Chemicals Ltd) in aseptic manner and the wound was cauterised. 
The part of the tail was cut into 2 mm pieces before placing in a labelled Nunc 
Cryotube (GibcoBRL) and rapidly frozen in liquid nitrogen and stored at -20°C.
3.2.2 Extraction of genomic DNA (gDNA) from mouse tails
3.2.2.1 Use of Wizard Genomic DNA Purification Kit
For each sample, 120 pi of 0.5M EDTA solution (pH 8.0) was added to 500 pi of 
Nuclei Lysis Solution (Promega) in a universal tube and chilled on ice. Tissue 
samples were lysed overnight at 55°C in 600 pi 0.5M EDTA/ Nuclei Lysis Solution 
containing 58 pg.ml'^ proteinase K (see 3.2.2.2, page 29). The samples were 
centrifuged and transferred to clean tubes. A volume of 200 pi Protein Precipitation 
Solution were added to the samples, vortexed and chilled on ice for 5 minutes. The
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mixtures were centrifuged at high speed for 4 minutes. The supernatants containing 
the DNA (leaving the protein pellets behind) were carefully transferred to clean 
tubes containing 600 pi o f isopropanol (Sigma) at room temperature. These 
solutions were gently mixed by inversion until the white thread-like strands of DNA 
formed a visible mass. The solutions were centrifuged at high speed for 1 minute 
and small white DNA pellets were formed. The supernatants were decanted and 600 
pi o f 70% ethanol, room temperature, were added to wash the DNA by inverting the 
tubes several times and centrifuged at high speed for 1 minute. The ethanol was 
aspirated and the DNA pellets were left in the tubes. The tubes were inverted on 
clean absorbent paper and air-dried for 30 minutes. The DNA pellets were 
rehydrated by addition of 200 pi DNA Rehydration Solution (Promega) overnight at 
4°C. The DNA was stored at 4°C.
3.2.2.2 Preparation of Proteinase K
Proteinase K was supplied as a lyophilised powder (Promega), It was reconstituted 
in 50mM Tris-HCl, pH 8.0, lOmM CaCl2 and stored at -20°C  in 20 pi aliquots.
3.2.3 Quantification and standardisation of nucleic acids
3.2.3.1 Quantification of nucleic acids
Samples o f gDNA were quantified with a GeneQuant RNA/DNA calculator 
(Pharmacia Biotech) using a 100 pi spectrophotometer cell.
3.2.3.2 Dilution of nucleic acids
Nucleic acid samples were diluted to working concentration with sterilised dH20. A 
concenti'ation of 50 ng pT  ^was used to dilute gDNA for PCR analysis.
3.2.4 Nucleic acid electrophoresis
3.2.4.1 Agarose gels
DNA analysis was performed on 0.7-3% agarose gels in a Tris acetate ethylene-di- 
amine-tetra-acetate (TAB) buffer (see 6.1.7.5, page 120). The gDNA was 
electrophoresed through a 0.7% agarose gel (Figure 5, page 47) and the PCR 
products on 2-3%.
Gels were cast from ultrapure electi'ophoresis grade agarose (GibcoBRL) and 
melted in TAB buffer. Ethidium bromide (from a stock of 1 mg .ml"') was added to 
cool gel to give a final concentration of 0.5 pg. ml"'. Samples were loaded with a 6x 
gel-loading buffer. Gels were electrophoresed in TAB buffer.
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3.2.4.2 Imaging and photography of Gels
Gels were visualised using a “Fotoprep I” ultraviolet (UV) transilluminator 
(Fotodyne Inc.) and Photographed with a Polaroid MP4 land camera (Polaroid) on 
Polaroid 667 (ASA 3000) film through a Wratten 22A filter (Kodak) or a Kaiser 
RAl CCD camera and UP-890CE Video graphic thermal printer (Sony).
3.3 PCR genotyping
3.3.1 PCR programme
Reaction tubes were submitted to initial cycle (3 min denaturing at 94°C, 1 min 
annealing at 55°C, 4 min extension at 72°C), 35 core cycles (40 sec at 93°C, 1 min 
at 55°C, 2 min at 72°C) and final cycle (40 sec at 93°C, 1 min at 55°C, 5 min at 
72°C) in a Techne PHC-3 thermocycler.
3.3.2 PCR conditions and AccI restriction
The DNA fragment including the rumpshaker region was amplified by PCR, using 
primers a-intron 3 and a-intron 4 sequenced C (5-CATCACCTATGCCCTGA-3) 
and D (5-TACATTCTGGCATCAGCGCCAGAGACTGC-3), respectively 
(Schneider et a l, 1992). The reaction was performed in 25 pi containing 0.4 pM of 
each primer, 0.2 mM dNTPs, 2.5 units of Taq polymerase (Promega) with the 
manufacturer’s ammonium buffer, 1.5 mM Mgch and 50 ng of DNA extract. This 
was overlaid with 50 pi of molecular biology grade mineral oil (Sigma) to prevent 
evaporation. The digested gDNA samples were stored at 4°C until further analysis. 
PCR products were pipetted beneath the oil layer and run on 2% agarose gels.
For the Accl restriction (Schneider et a l, 1992), 9 pi of PCR product were added to 
6 pi of sterile dH20 containing 10 units restriction enzyme Acc\ and lOx buffer, and 
this mix was incubated at 37°C for 2-3 hours. Restricted DNA fragments and 
control (undigested PCR products) were run on 3% agarose gel (Figure 5, page 47).
Positive and negative controls were included with each set o f samples. A control 
reaction was also included with the sample omitted and replaced by sterilised dH2 0  
to ensure that there were no contaminating nucleic acids.
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3.4 Tissue fixation
3.4.1 Fixatives
3.4.1.1 Karnovsky’s modified fixative (Paraformaldehyde/Glutaraldehyde
2%/5%)
This fixative (Griffiths et a l,  1981) was used for the preservation of tissues 
prepared for resin embedding for the light and electron microscopy. Fixed tissues 
were stored at 4°C until processed. (For preparation see 6.1.3.1, page 110).
3.4.1.2 4% Paraformaldehyde
4% paraformaldehyde in phosphate buffered saline (PBS) was used for the 
preservation of tissues intended for immunohistochemistry. After fixation, tissues 
were post-fixed in the same fixative for 3-6 hours and then transferred to 20% 
sucrose in PBS for 24 hours and rapidly frozen. (For preparation see 6.1.3.2, page 
111).
3.4.1.3 Periodate-Iysine-paraformaldehyde (PLP) fixative
P-L-P fixative (McLean and Nakane, 1974) was used for the preservation of tissues 
destined for immunohistochemistry, especially for staining microglia. After 
fixation, tissues were post-fixed in the same fixative for 3-6 hours and then 
transferred to 20% sucrose in 0.1 M phosphate buffer for 24 hours and rapidly 
frozen. (For preparation see 6.1.3.3, page 111),
3.4.1.4 Buffered neutral formaldehyde (4%BNF)
BNF fixative was used for the preservation of tissues for paraffin embedding and 
subsequently used for immunohistochemistry and routine haematoxylin and eosin 
(H&E) staining. BNF fixed tissues were stored at room temperature until processed. 
(Forpreparation see 6.1.3.4, page 111).
3.4.2 Fixation techniques
Mice were humanely euthanased using an overdose of carbon dioxide or halothane 
in a closed chamber. The carcass was then pinned on a wooden board. The chest 
was also opened and the pericardium was removed. To flush the vasculature, the 
right atrium was punctured to allow drainage; a needle was inserted into the left 
ventricle and PBS was injected under moderate pressure. Once the effluent was 
clear, the fixative was injected. Between 100 ml and 200 ml of fixative was 
injected, depending on the age of the mouse. After fixation the animal was left in
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fixative for up to 3 hours before dissection. The brain, optic nerves and spinal cord 
were removed, cut into appropriate blocks, placed in fixative and stored until 
processing.
3.5 Tissue processing and sectioning
3.5.1 Paraffin wax processing and sectioning
BNF-fixed tissues for paraffin wax embedding were processed using a Shandon 
Elliot automatic tissue processor (Histokinette). These tissues were passed through 
different graded dehydrating solutions (see 6.1.4.1, page 112) and blocked out with 
wax at 60°C. 8pm sections were cut on a Biocut 2035 microtome (Leica), mounted 
onto APES-coated slides (see 6.1.1, page 110) and placed in the oven at 56°C 
overnight.
3.5.2 Resin processing and sectioning
Tissues for Araldite resin embedding were processed using a Lynx el microscopy 
tissue processor (Leica). The tissues were passed through different graded alcohols 
(see 6.1.4.2, page 113) and infiltrated with resin. For blocking out, the tissues were 
oriented in resin-filled rubber moulds and placed in the oven at 60°C overnight for 
polymerisation. Using an Ultracut-E ultratome (Reichert-Jung), 1pm sections were 
cut with a glass knife from resin blocks and mounted on glass slides for light 
microscopy while 70nm sections were cut with a diamond knife and mounted on 
200-mesh 3.06mm-diameter copper grids for electron microscopy.
3.5.3 Cryopreservation and sectioning
Freshly dissected tissues and tissues fixed with P-L-P fixative or 4% 
paraformaldehyde were suspended in Tissue-Tec O.C.T compound (Miles Inc) and 
frozen in isopentane cooled in liquid nitrogen. The frozen blocks were wrapped 
with NescoFilm (Bando Chemical Ind. Ltd.) and stored at -20°C. 15pm sections 
were cut using an OTF cryostat (Bright Instrument Company) and mounted onto 
APES-coated slides (see 6.1.1, page 110) and stored at -20°C.
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3.6 Staining techniques
3.6.1 Light microscopy
3.6.1.1 Haematoxylin and Eosin (H&E)
8 pm paraffin sections and 15 pm cryopreserved sections were stained with H & E  
(see 6.1.5.3, page 116) and mounted in DPX (BDH).
3.6.1.2 Haematoxylin
To counterstain, paraffin and cryopreserved sections were stained with 
haematoxylin (see 6.1.5.4, page 117).
3.6.1.3 Methylene blue/ azure II
1pm resin sections were stained with methylene blue/azure II (see 6.1.6.1, page 
118). The slides mounted with sections were placed on a 60°C hot plate, flooded 
with stain for 30-60 sec and rinsed in running water. After drying, slides were 
mounted in DPX.
3.6.2 Electron microscopy (EM)
For electron microscopy, the 70nm resin sections were stained using uranyl acetate 
and lead citrate (see 6.1.5.5, page 117).
3.7 Quantitative studies (ciassicai methods)
3.7.1 Quantification of glial cells
Transverse 1pm resin sections of the second segment of the cervical cord (C2), 
post-fixed in osmium tetroxide and stained with methylene blue/azurell, were used 
for quantification of glial cell nuclei. Quantification was performed using a lOOx oil 
immersion lens with 6.3x eyepieces, one o f which contained a 100 square graticule 
(Graticules Ltd). The white matter areas subjected to counting were the ventral 
columns immediately adjacent to the ventromedian fissure and its continuation onto 
the ventral surface of the cord. Two sections, 15 pm apart were examined. On each 
section, two fields, one on each half of the cord, were counted. Thus a total 300-400 
squares were estimated. Endothelial nuclei were ignored. Only nuclei having 
morphological criteria of glia were considered.
The mean and the maximum nuclear lengths were measured in longitudinal sections 
of the caudal segments of ceiwical cord using a calibrated eyepiece. The mean
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length of 50 nuclei (oligodendrocytes, astrocytes and microglia) was calculated. 
Areas of white matter were calculated from Polaroid light microscopy images using 
Sigma Scan/Image measurement software (Jandel Scientific Software) and 
SummaSketch III graphics tablet (Summagraphics). Corrected total glial cell counts 
and corrected glial cell densities were calculated using Abercrombie’s correction 
(Sturrock, 1983).
3.7.2 Differential glial cell count
Based on nuclear morphology, the glial nuclei (oligodendrocytes, astrocytes and 
microglia) were counted as previously described for quantification of glial cells.
3.7.3 Dead cell numbers
The same two sections used for quantification of glial nuclei were considered for 
estimating the dead cell numbers. Pyknotic nuclei were counted in the total white 
matter using a lOOx oil immersion lens. Pyknotic nuclei for the two sections were 
averaged and used to represent the counts for that particular animal. Due to the lack 
of any morphological characteristics o f a particular population, the pyknotic nuclei 
arising from a particular glial cell type are indistinguishable.
3.7.4 Myelin volume
The same blocks used for the glial cell quantification were trimmed and 70 nm 
ultrathin sections were cut for electron microscopy. Random fields from the ventral 
columns were photographed with AEI EM6B electron microscope at approximately 
5000x magnification and printed at approximately 2x magnification. Calibration 
was achieved by photographing a diffraction grating of known size for each set of 
prints.
These measurements were performed on the electron micrographs masked with 
transparent ruled squares of 2.25 cm^. The myelin volume was calculated by 
counting o f the number of intercepts hitting the myelin lamellae in each micrograph 
relative to the total intercepts (Williams, 1977). Ten-12 photographs were counted 
per animal.
3.8 Immunohistochemistry
Resin and paraffin sections were stained with PAP technique and cryostat sections 
were stained either with indirect immunofluorescent techniques, PAP or ABC. 
Buffers were applied to sections to block non-specific binding and increase tissue 
permeability. Sections were not allowed to dry throughout sequence procedures of
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staining, therefore, all incubation with antibodies and links were performed in a 
humid chamber at room temperature, unless stated. Control sections were also 
included, with the primary antibodies omitted. Immunostained sections were stored 
in the dark at 4°C.
3.8.1 Labelling markers
Commercially available and other antibodies were used and their sources and 
dilution are illustrated in Table 2, page 37.
Anti-BrdU antibody (Sigma) was applied to detect the BrdU incorporated into DNA 
of dividing cells. Anti-Caspase-3 antibody (R&D systems) was used to recognise 
apoptotic cells. Anti-NG2 chondroitin sulphate proteoglycan antibody (Chemicon 
International Inc.) was used to selectively stain oligodendrocyte progenitors. Anti- 
adenomatous polyposis coli (APC) antibody (Oncogene) was employed to 
distinguish mature oligodendrocytes (Fernandez et a l, 2000; McTigue et a i, 2001). 
Anti-CD45 antibody (Serotec) and F4/80 hybridoma supernatant (Serotec) 
recognise pan-leukocyte and microglial/macrophage-specific epitopes, respectively, 
and were used to identify microglia. For staining astrocytes anti-glial fibrillary 
acidic protein (GFAP) antibody (Dako) was applied (Bignami et a l,  1972). Anti- 
MBP antibody (NP. Groome, Oxford, UK) was used to stain central compact 
myelin. Anti-PLP C-terminal antibody (NP Groome, Oxford, UK) recognises the 
carboxy terminus (amino acids 271 to 276) of both PLP and DM20 protein isoforms 
(Fanarraga et a l ,  1993).
3.8.2 Immunofluorescence
Secondary antibodies were labelled with fluorescein isothiocyanate (FITC) and 
Texas red (TxR) (Table 3, page 37) and sections were examined by epifluorescence. 
FITC absorbs light with a wavelength 495 nm and emits it at 525 nm, which can be 
visualised as green light using a blue filter. TxR absorbs light at 596 nm and emits it 
at 620 nm, which can be visualised as red light using a green filter. 4,6-diamidino-2- 
phenylindole (DAPI) provides a fluorescent light with excitation of 345 nm and 
emission of 455.
3.8.3 Cryostat sections
Sections at -20°C were allowed to warm to room temperature and then washed in 
PBS (see 6.1.7.1, page 119), twice for 10 minutes. Between steps, sections were 
washed two changes with PBS for 10 minutes if  required. Unfixed sections were 
fixed in 4% PF for 20 minutes and then washed with PBS. At this stage the sections 
are ready for different treatments. After completion of staining, sections were
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mounted in Citifluor antifade medium (UCK Chem Lab) and the coverslips sealed 
with nail varnish.
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Table 2. Primary antibodies
Primary antibody Host Isotype Dilution Source
Anti-PLP C- 
terminal
Rabbit
polyclonal
IgG 1:600 Groome
Anti-MBP Rat monoclonal IgG 1:500 Groome
F4/80 Rat monoclonal IgG2b 1:1000 Serotec
Anti-GFAP Rabbit
polyclonal
IgG 1:1000 DAKO
Anti-BrdU Mouse
monoclonal
IgGl 1:2500 Sigma
Anti-APC Mouse
monoclonal
IgGzbk 1:100 Oncogene
Anti-CD45 Rat monoclonal IgG 1:600 Serotec
Anti-NG2 Rabbit
polyclonal
IgGl 1:150 Chemicon
Anti-caspase-3 Rabbit
polyclonal
IgG 1:5000 R&D
T able 3. Secondary antibodies
Secondary antibody Dilution
Goat-anti-mouse IgGl TxR 1:80
Goat anti-rabbit IgG FITC 1:80
Goat anti-rat IgG FITC 1:50
Goat anti-mouse IgG2b FITC 1:100
(Sourced from Southern Biotech)
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3.8.4 Peroxidase anti-peroxidase (PAP)
3.8.4.1 Preparation of Slides
3.8.4.1.1 Resin sections
Resin was removed by immersion of slides, with rotation, in sodium ethoxide (50% 
ripened sodium ethoxide in 50% absolute alcohol) for 30 minutes. Slides were 
washed, 6 changes, in absolute alcohol for 30 minutes. Endogenous peroxidase 
activity was quenched using 3% hydrogen peroxide in water for 30 minutes. 
Sections were again washed in running water for 30 minutes.
3.8.4.1.2 Paraffin sections
Paraffin sections dewaxed in xylene and hydrated through alcohols. Endogenous 
peroxidase activity was quenched using 3% hydrogen peroxide in water for 30 
minutes. Sections were again washed in running water for 30 minutes.
3.8.4.2 PAP staining
After washing with running water, sections were coated with 10% normal goat 
serum (NGS) in PBS for about 2 hours at room temperature. Excess NGS was 
removed and the primary antibody, diluted in 1% NGS/PBS, was immediately 
applied and sections were incubated overnight at 4°C. The following day sections 
were allowed to warm to room temperature and were washed in PBS, 6 changes, for 
30 minutes. The appropriate link antibody diluted in 1% NGS was applied for 1 
hour at room temperature and washed in PBS 6 changes for 30 minutes. Sections 
were incubated with PAP complex (Table 4, page 39) for 30 minutes at room 
temperature and washed in PBS, 6 changes, for 30 minutes. The chromogen 
reaction was developed in filtered PBS containing 0.5 mg.mf^ 3,4,3,4- 
tetraminobipheyl hydrochloride (DAB) and 0.003% hydrogen peroxide until the 
required colour change was seen (30 seconds to 5 minutes). DAB was removed by 
washing in PBS for 2 minutes and running water for 5 minutes. Sections were 
immersed in 1 % Osmium/Caccodylate buffer for 2 minutes before washing.
Sections were dehydrated through alcohols, cleared and mounted in DPX.
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Table 4. Link antibody and PAP complexes
Link antibody Dilution PAP complex Dilution Source
Goat-anti-
rabbit
1:10 Rabbit 1:40 ICN
3.8.5 Avidin biotin complex (ABC)
3.8.5.1 Preparation of Slides
3.8.5.1.1 Paraffin sections
Paraffin sections were prepared as described for PAP.
3.8.5.1.2 Cryostat sections
Cryostat sections post-fixed with P-L-P fixative were washed in PBS, 6 changes, for 
20 minutes.
3.8.5,2 ABC staining
Sections were washed in PBS, 6 changes, for 20 minutes between steps and all 
reagents were diluted in PBS. Endogenous peroxidase activity was quenched by 
immersing the slides in 0.3% hydrogen peroxide in ethanol for 20 minutes. Washed 
PBS sections were blocked in 10% NGS for 30 minutes. Excess NGS was removed 
and the primary antibody diluted in 1% NGS was applied for 1 hour. The sections 
were washed and the appropriate link antibody was applied for 45 minutes. The 
sections were then washed in PBS and incubated in avidin-biotin complex (Elite 
ABC) (Table 5, page 40) for 45 minutes. The chromogen reaction was developed in 
filtered PBS containing 0.5 mg.ml"^ DAB and 0.003% hydrogen peroxide until 
required colour change was seen (30 seconds to 5 minutes) and then washed. The 
sections were exposed to 0.01% osmium tetroxide for 30 seconds to increase the 
chromogen intensity. The sections were washed, counterstained with haematoxylin 
(see appendix 6.1.5.4 , page 117), dehydrated through alcohol (see appendix 6.1.5.2, 
page 115), cleared and mounted in DPX.
The paraffin sections were stained for MPB and the cryostat sections were stained 
for microglial epitopes F4/80 as well as CD45.
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Table 5. Link antibody and Avidin biotin Complex (ABC)
Link antibody Dilution ABC Dilution Source
Rabbit-anti-rat IgG 1:100 10 p,l of A and B in 625 pi PBS Vector labs
3.8.6 BrdU staining of proliferating cells
A combination of fresh cryopreserved and 4% PF cryopreserved sections were used 
for BrdU staining. Slides were immersed in 6 M HCl, 1% triton x-100 for 10 
minutes. The sections were washed in 0.2% triton x-100 in PBS. Anti-BrdU 
antibody, 1:2500, diluted in 0.2% triton x-100 was applied to the sections for 3 
hours and then washed in PBS. The sections were incubated with goat anti-mouse 
IgGl TXR secondary antibody at 1:80 for 30 minutes. The sections were then 
washed and mounted.
3.8.7 NG2 staining of oligodendrocytes
Cryostat sections post-fixed with P-L-P fixative were permeabilised in methanol at 
-20°C for 10 minutes and washed in PBS. The sections were then incubated with 
anti-NG2 at 1:150 in PBS at 4°C overnight and washed. Goat anti-rabbit IgG FITC 
secondary antibody was applied to the sections at 1:80 in PBS for 30 minutes and 
washed. The sections were counterstained with DAPI, washed and mounted.
3.8.8 APC staining of oligodendrocytes
Sections were immersed in 0.5% triton x-100 for 30 minutes and non-specific 
binding was blocked with 0.1% triton x-100, 0.2% pig skin gelatin in PBS for 30 
minutes. Excess blocking solution was removed and anti-APC antibody at 1:100 
diluted in blocking solution was applied to the sections at 4°C overnight. The 
sections were washed and incubated with goat anti-mouse IgG2b FITC secondary 
antibody, 1:100, diluted in blocking solution for 30 minutes. The sections were 
washed, stained with DAPI, washed and mounted. APC has been used to label 
mature oligodendrocytes (Mays, 1999; Fernandez et a l, 2000; McTigue et a l ,  
2001). As it has been reported to label some astrocytes in certain situations (Leroy 
et a l,  2001) we double labelled spinal cords for APC Figure and for GFAP, a 
marker for astrocytes; no double labelled cells were seen (Figure 6,page 48) 
suggesting that in our hands we are not detecting astrocytes with the APC antibody.
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3.8.9 GFAP staining of astrocytes
Sections were permeabilised in methanol at -20°C for 10 minutes and washed in 
PBS. The sections were then coated with anti-GFAP antibody at 1:1000 overnight at 
4°C and washed in PBS. The sections were again coated with goat anti-rabbit FITC 
secondary antibody at 1:80 for 30 minutes. Finally, the sections were stained with 
DAPI, washed and mounted.
3.8.10 CD45 staining of microglial
Sections were permeabilised in methanol at -20°C for 10 minutes and washed in 
PBS. The sections were then incubated with anti-CD45, 1:600, in PBS at 4°C 
overnight and washed. Goat anti-rat IgG FITC secondary antibody was applied to 
the sections at 1:50 for 30 minutes and washed. The sections were counterstained 
with DAPI, washed and mounted.
3.8.11 Caspase-3 staining of apoptotic cells
Sections were coated with blocking solution containing 0.1% triton x-100, 0.2% pig 
skin gelatin in PBS for 30 minutes. Excess blocking solution was removed and anti- 
caspase-3 antibody, 1:4000, diluted in blocking solution was applied to the sections 
at 4°C overnight and washed. The sections were washed and incubated with goat 
anti-rabbit IgG FITC secondary antibody, 1:80, diluted in blocking solution for 30 
minutes. The section were washed, stained with DAPI, again washed and mounted.
3.8.12 DAPI Staining
Following immunostaining, cell nuclei were visualised with Ipg.lm'* 4,6- 
diamidino-2-phenylindole (DAPI), the fluorescent dye, for 30-60 seconds. Non- 
immunostained sections were also stained with DAPI.
3.8.13 Double staining of BrdU-labelled sections
Sections were first immunostained with appropriate primary antibody, as described 
for each single immunostaining method, and then the procedures for BrdU were 
followed. The sections were washed and mounted.
3.8.14 Double staining of Caspase-3 Cells
Sections were first immunostained with appropriate primary antibody, as described 
for each single immunostaining method, and then immunostaining for caspase-3 
was followed. The sections were washed and mounted.
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3.9 Quantitative studies (immunolabeiled 
methods)
3.9.1 Quantification of MBP-labelled myelin
Resin sections (l|Lim) were immunolabeiled for MBP using the PAP technique. 
Using a x40 dry objective four areas of ventral column, two each side o f the 
ventromedian fissure, were imaged using the CCD camera and stored in the 
computer. Images were converted to grey scale and adjusted to give optimum 
contrast and brightness. Using the segmentation software (Image Pro Plus v4. 
Media Cybernetics) the dark areas (MBP staining) were separated from the 
remaining background. This was accomplished initially using a black image on a 
translucent background so that any false staining of non-myelinated tissue could be 
removed. In the majority of cases no manual adjustment was necessary. The image 
was then converted to a black on white format. For each image, a square area of 
interest (AOI) of 2500p,m^ was placed at one side and the area of black (MBP- 
stained myelin) within the AOI was measured. The AOI was then moved to the 
other side of the image and the process repeated. For each animal a total o f eight 
AOI were measured. From these data the density of MBP-stained myelin 
(pm^)Zmm^ of white matter was calculated. As the white matter area had been 
determined previously for the glial cell quantification, we could determine the total 
area of MBP-stained myelin in white matter of a transverse section of spinal cord.
3.9.2 Quantification of BrdU-labelled cells
Cell counts were performed on cryosections (15p,m) of the ventral columns, 
adjacent to the ventromedian fissure, from rostral cervical spinal cord. Images of 
BrdU-labelled or DAPI-labelled nuclei were collected at x20 objective using a CCD 
camera system (Photonic Science Colour Coolview) and stored in the computer. 
Approximately 20 images of BrdU nuclei and 6 of DAPI nuclei were obtained from 
each animal. For each BrdU-labelled image a frame (35804 pm^) outlining the AOI 
was placed on the screen. Counting parameters were set to include bright objects o f 
area between 4 and 200pm^ within the AOI or touching the top or left side but 
excluding those touching the bottom or right sides. Automated counts were made 
with adjustments for any touching objects or false images due to dirt or debris. 
DAPI-labelled nuclei were counted in a similar manner with an AOI of 10,000pm^. 
The density of BrdU-labelled nuclei and DAPI-stained nuclei (nuclei/mm^) and the 
labelling index (LI) (BrdU nuclei/DAPI nuclei x 100) were calculated.
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3.9.3 Quantification of APC+ cells
Cell counts were performed on cryosections (15pm) of the ventral columns, 
adjacent to the ventromedian fissure, from rostral cervical spinal cord. Images of 
APC-labelled cells (green channel) and DAPI-labelled nuclei (blue channel) from 
the same sampling area were collected at x20 objective using a CCD camera system 
(Photonic Science Colour Coolview) and stored in the computer. The green and 
blue channels were merged using Adobe Photoshop (Adobe systems Inc., San Jose) 
and the image quality adjusted. For each combined image, a frame (35804pm^) 
outlining the AOI was placed on the screen. The number of APC+ cell bodies 
containing a DAPI-stained nucleus was counted within the AOI or touching the top 
or left side but excluding those touching the bottom or right sides. The density of 
DAPI-labelled nuclei was counted automatically with an AOI of 10,000pm^. The 
density of APC-labelled cells and DAPI-stained nuclei (nuclei/mm^) and the 
percentage o f APC+ cells (APC cells/DAPI nuclei x 100) was calculated.
3.9.4 Quantification of NG2+ and CD45+ cells
These cells were quantified as described for the APC+ cells.
3.9.5 Quantification of caspase-3+ cells
Cell counts were performed on cryosections (15pm) of the ventral columns, 
adjacent to the ventromedian fissure, from rostral cervical spinal cord. Images of 
caspase-3-labelled cells were collected at x20 objective using a CCD camera system 
(Photonic Science Colour Coolview) and stored in the computer. For each image, a 
frame (35804 pm^) outlining the AOI was placed on the screen. The number of 
caspase-3+ cell bodies was counted within the AOI or touching the top or left side 
but excluding those touching the bottom or right sides. The density of DAPI-stained 
nuclei was taken from the sections stained for APC/DAPI. The density of caspase- 
3-labelled cells and the percentage of caspase-3+ cells (Caspase-3+ cells/DAPI 
nuclei x 100) was calculated.
3.9.6 Calculation of cell numbers
Quantification of cells or nuclei was determined by their density in the ventral 
funiculi. As the area of the white matter varied between different genotypes we 
calculated the total number of cells/nuclei in the white matter of a transverse 
section. This calculation assumes that the density is equally distributed throughout 
the white matter when there is variation between tracts and at different ages. In fact 
the nuclear density alters across the width of the ventral column, being greater in the 
central region adjacent to the grey matter. The alternative strategy is to define a
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precise sub-region of the ventral column in which to calculate total numbers, a task 
that would be problematic to ensure consistent identification of the same region. 
The calculation based on the total white matter area therefore offers an acceptable 
way of comparing cell numbers between different genotypes and ages.
3.10 Statistical analysis
3.10.1 Group sizes
The number of animals included in a group varied between ages, genotype and 
techniques. In general, 4 or more animals were included in a group. When a 
developmental profile was followed, for example, cell counts between PIO and P30, 
the number of animals was increased to 6 or even 10 or more at key ages (e.g. P20 
and P30) with sizes o f 4 at P I5 and P25. If  only a single analysis point was used, 
group sizes were always 6 or more.
3.10.2 Data presentation
Graphs are presented as mean ± SEM.
3.10.3 Statistical tests
As group sizes were always relatively small no assumptions were made that the data 
was distributed normally. Groups were first compared using one-way Analysis Of 
VAriation (ANOVA). If  a significant difference (p<0.05) was detected, individual 
groups were compared using the Bonferroni multiple comparison test. P was taken 
at < 0.05.
Further details of group sizes, numerical values and P values for all analyses are 
presented in (7. Appendix 2. Details o f statistical analyses, page 121).
3.11 Western blotting
3.11.1 Protein extraction
Protein was extracted from mouse spinal cord and brain that had been freshly 
dissected, rapidly frozen in liquid nitrogen and stored at -80°C until required. All 
solutions were chilled on ice before use. The tissue samples were homogenised in 
an extraction buffer containing (0.85 M sucrose, 10 mM Hepes (pH 7.4), 2 mM 
DDT and 1 mM TLCK) for 10 seconds using a polytron homogeniser set at 
maximum speed. Aliquots of the homogenates were removed to represent total
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homogenate fractions. The remaining homogenates were transferred to the Beckman 
SW41 rotor tubes and 0.25 M sucrose/ 10 mM Hepes (pH 7.4) solution was gently 
added until the volume was about 1cm from the top of the ultracentrifuge tubes. The 
homogenates were centrifuged at 70,000g for 90 minutes at 4°C. This produced a 
biphasic solution with cellular debris left in the lower phase (0.85 M sucrose), lipid 
floating on top of the upper phase (0.25 M sucrose) and myelin protein trapped at 
the interface between two phases. The myelin protein was transferred to clean tubes 
and hypotonically lysed for any remaining cellular organelles by adding chilled 
dH20. This was centrifuged at 23,000g for 30 minutes at 4°C. The supernatant was 
discarded and the process was repeated 3 times with the final centrifugation at 
17,000g for 30 minutes. The myelin pellets were resuspended in 10 mM Hepes (pH 
7.4) containing protease inhibitor (0.5 mM PMSF, 10 pg.mf* leupeptin, 10 pg.ml'^ 
aprotinin, 10 fig.ml"  ^ trypsin inhibitor and 1 mM benzamidine). The protein 
concentration was measured using the BCA assay (Pierce Ltd). The myelin protein 
and homogenate fractions were stored at -80°C until required.
3.11.2 Precipitation of protein
For GFAP immunoblotting the total homogenate was precipitated. 150 pi aliquot of 
each sample was made up to 900 pi by adding chilled dH20 and 100 pi of a 50% 
(wt/vm) of TCA. The samples were then incubated on ice for 30 minutes and 
centrifuged at 13,000g for 15 minutes at 4 °C. Pellets were resuspended with 100 
mM Tris base pH 10.4 and proteins concentration was measured as previously 
mentioned.
3.11.3 SDS-Polyacrylamide gel electrophoresis
3.11.3.1 SDS-Polyacrylamide gel preparation
Proteins were resolved on a vertical SDS-polyacrylamide mini-gel produced by 
polymerisation of acrylamide cross-linked with N,N"-methylene bisacrylamide at a 
ratio of 30:8. The catalyst for the reaction was ammonium persulphate and the 
accelerator was N,N,N,N',-tetramethylethylenediamine (TEMED). Routinely, 
proteins were separated on a 12.5% acrylamide resolving gel and a 4% stacking gel.
3.11.3.2 Protein electrophoresis
Aliquots o f samples (myelin and homogenates) were made up to 20 pi with dH20 
and then to 30 pi final volume with denaturing buffer containing (25 mM Tris, 192 
mM glycine, 0.1% SDS). The samples were denatured at water bath 90°C for 4 
minutes and loaded onto the gel with size markers as controls.
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The samples were electrophoresed at room temperature in a mini-PAGE-rig (ATTO 
Corp.) in a buffer containing 25 mM Tris 192 mM glycine, 0.1% SDS) at 20mA 
constant current per gel for 90 minutes until the dye front reach the gel bottom.
3.11.3.3 Electrophoresis protein transfer
The separated proteins were transferred onto a polyvinylidene fluoride (PVDF) 
microporous membrane (Millipore) in a semi-dry blotter (The W.E.P. Company). 
Layers were arranged from the bottom to the top, a 3MM paper sheet (Whatman) 
soaked in Anode 1 buffer (0.3 M Tris (pH 10.4), 7.5% MeOH), 2 sheets soaked in 
Anode 2 buffer (0.025 M Tris (pH 10.4), 7.5% MeOH), PVDF membrane treated 
with 100% methanol, rehydrated in dHaO and equilibrated in Anode 2 buffer, the 
gel equilibrated in cathode buffer (0.025 M tris/40 mM glycine (pH 9.4), 7.5% 
MeOH and 3 sheets soaked in cathode buffer. The transfer was performed at 100 
mA constant current for 1 hour. The membrane was stained with Ponceau stain to 
check for equal loading and efficiency of transfer.
3.11.3.4 Immunostaining
The membrane was blocked by immersing in TBS blocking buffer containing 5% 
dried semi-skimmed milk and 0.1% Tween-20 (T-TBS) for 1 hour at room 
temperature. The primary antibodies (see below) were diluted in blocking buffer 
and applied for 2-3 hours at room temperature. The membrane was then washed 3 
times in T-TBS for 10 minutes. The link secondary antibody (see below), diluted in 
blocking buffer, was applied for 1 hour at room temperature. The membrane was 
washed again in T-TBS (pH 7.6) 3 times for 10 minutes. The membrane was 
incubated in equal volumes of luminal enhancer solution and stable peroxide 
solution (Pierce Ltd) for 1-2 minutes at room temperature. The membrane was 
wrapped in Saran wrap and exposed to X-omat imaging film (Kodak) in a 
radiography cassette for 1-5 minutes. The film was finally developed in an 
automatic processor (Dupont Cronex CX-130).
Membranes were incubated with 1:50000 diluted anti-PLP C-terminal rabbit 
polyclonal antibody (NP. Groome, Oxford, UK), 1:10000 diluted anti-MBP rat 
monoclonal antibody (NP. Groome, Oxford, UK), 1:2000 diluted anti-MAG 
polyclonal antibody (NP. Groome, Oxford, UK), 1:10000 diluted anti-CNP 
polyclonal antibody (PJ. Brophy, Edinburgh, UK), and 1:200000 diluted anti-GFAP 
rabbit monoclonal antibody (Sigma). The immunocomplexes were detected with 
anti-rabbit HRP-linked IgG (SAPU) or anti-rat HRP-linked IgG (Sigma) secondary 
antibody.
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Fig. 5A. Examples o f  gD N A  extracted from m ouse tails and 
electrophoresed on 0.7%  agrose gel (size marker: 'k-DNA/HindlU).
5 G 7 8
Fig. 5B. Products o f  PCR and PCR products digested using AccI, used for 
identification o f  rsh mutant animals. Lane 1, 3, 5 and 7 are the PCR 
products. Lane 2, 4, 6 and 8 are PCR products digested with AccI enzyme 
at 37 °C. Only lane 4 and 6 are successfully digested, therefore, they 
represent rsh mutation, (size marker (M): (j)X174-DNA///ufeIII).
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Fig. 6. Double immunofluorescence for APC and GFAP. 
Sections from ventral white matter o f C3H rsh at P20. No 
double labelled cells are evident. Bars top = lOOum; 
bottom = 20um
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4. Results
4.1 Clinical manifestations of rumpshaker
4.1.1 Introduction
The rumpshaker {rsh) mutation arose spontaneously in C3H mice at the MRC 
Radiobiology Unit in 1988. These mutant mice were crossed with the 101 strain to 
improve breeding (the usual practice at that time in the unit) and donated to 
Glasgow University Veterinary School for further study and maintenance. The mice 
on the C3H/101 background showed a generalised tremor related with 
hypomyelination in the CNS and an X-linked mode of inheritance suggesting 
possible role o f Pip gene (Griffiths et a l ,  1990). Importantly, they live a normal 
length of time and affected animals reproduce. The rumpshaker mutation was 
identified as a recessive point mutation causing an amino acid transition (Ile^^^Thr) 
in the murine Pip gene (Schneider et a l, 1992). jim py  mutant mice and rumpshaker 
have been indicated to be allelic to each other (Cattanach and Beechey, 1991).
4.1.2 Materials and Methods
4.1.2.1 Mouse breeding
The animals used in all experiments are described in mouse breeding (see 3.1.1, 
page 27). Mutant male mice from the two genetic backgrounds and their normal 
littermate males as controls were used for the current work. PCR (see 3.3, page 30) 
was used to confirm the genotype o f 10 day postnatal (PIO) or younger mice as well 
as female carriers for the mutated allele, which were used for breeding.
4.1.2.2 Rotarod
Mice were assessed on the Rotarod, as described in (4.1.2.2, page 49) at P20 and 
P30.
4.1.3 Results
4.1.3.1 Clinical presentation
Physically rumpshaker mutants from the two backgrounds develop a generalised 
tremor at 10-13 days. This neurological abnormality is clearly noted during
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movement o f animals while it ceases at rest or during sleep. As animals age, the 
tremor is confined to the hindquarters and peaks at approximately 20-25 days. 
Compared with 03H rsh, which survive to reproduce, 057 rsh develop seizures 
after 25 days and die at about 4-5 weeks.
4.1.3.2 Rotarod
Animals were placed on a suspended horizontal rotating rod, which gradually 
accelerated from 3 to 30 rpm and the time until falling was recorded. Since many 
wild type mice do not fall off the rod and generally remain on it for a long periods 
of time, a maximum reading (500 sec) was set. In the actual experiment there was 
variability between individual mice scoring.
The 057 WT and 03H WT groups stayed on the rod for a significantly longer time 
than did the mutants. The 03H  rsh also stayed for a significantly longer time than 
the 057 rsh. The time of staying on the rod was slightly decreased at P30 (Figure 7, 
page 52).
4.1.3.3 Body weight
Growth is normally closely linked with chronological age. The rumpshaker 
mutation is likely to influence the weight gain of the mutant animals. All groups 
studied showed steady increase in weight up to P30. The 057 wild types weighed 
significantly less than their 0 3 H counterparts. The mutant animals were relatively 
smaller than normal littermates. The four groups of animals, on the basis of weight 
gain, were represented in the order 03H  WT>03H rsh>C51 W T>057 rsh (Figure 8, 
page 52).
4.1.4 Discussion
The severity of the Pip gene mutant phenotypes is highly dependent on the nature of 
mutation and the genetic background. Oharacteristic features are common among 
the Pip gene mutants including man. Generalised body tremors, the first clinical 
sign which identify the mutant animals, are noted early during the first postnatal 
weeks. The tremors are usually obvious at P I0-13 in mutant mice and before 10 
years o f age in human. The severe phenotype of the C57 rsh mutation is closely 
similar to jim py  mutant mice (Duncan, 1990) as both of the mutants develop 
seizures at about P25 and die around P30. As the frequency and intensity of the 
seizures increase the condition causes the death of the mutant animals between 4-5 
weeks (in general during seizures). In contrast to the above severe phenotypes, C3H 
rsh is the mild fonn of the mutation and manifests no seizures. Additionally, the 
tremor gradually disappears as the animals age. Moreover, mutations in the Pip
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gene appear to influence gaining of body weight. This criterion is remarkable in the 
rsh mutants which weigh less than their normal littermates on either genetic 
background. Consistent with this finding, jim py  mutants are also lesser in their 
weight when compared to their wild type littermates (Bolivar and Brown, 
1994).When assessing locomotor activities on the Rotarod, the rumpshaker mutant 
mice also spend less time than their respective wild type animals.
Patients with PMD/SPG2 due to amino acid substitutions also show considerable 
heterogeneity of clinical presentation and signs. Much of this has been ascribed to 
the different mutations and to some extent this may well be true. However, variation 
within families has been noted (for review see Hodes et a l ,  1993; Baron et a l, 
1994) and some o f the heterogeneity may be due to non-PZP gene-related 
polymorphisms within the human genome.
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Fig. 7. Tim e on Rotarod for groups o f  mice. There is no difference between wild type 
m ice at either age. The C57 rsh values are lower than w ild type at both ages w hile the 
C3H rsh are lower only at P20. The tw o mutants differ from each other at P30.
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Fig. 8. M ouse body weights. The C57 wild type is less heavy than its C3H counterpart 
after PIO. The C3H wild type and mutant have similar w eights between PIO and P30. 
The C57 mutant differs from both its wild type and the C3F1 rsh after PIO.
4.2 Neuropathology of rumpshaker
4.2.1 Introduction
Neuropathologically, the CNS (but not PNS) of C3H rumpshaker mice shows 
generalised hypomyelination. The appearance of myelin sheaths can vary from 
poorly compacted oligodendrocyte processes to the thin sheaths, which may be 
compacted or occasionally vacuolated. Sheaths of many smaller axons are of a 
similar thickness to those of equivalent axons in normal mice. The total number of 
glial cells and in particular the oligodendrocytes, appears increased even at one year 
of age (Griffiths et a l, 1990). Many of these oligodendrocytes are likely to be 
metabolically active with prominent RER and Golgi apparatus (Griffiths et a l, 
1990). Unlike many Pip gene mutant animals, cell death was not thought to be a 
prominent feature in rumpshaker (Schneider et a l,  1992). In separate projects to 
attempt to rescue mutant phenotypes by transgenic complementation it was 
necessary to move the rsh mutation to a C57BL/6 background. However, as the 
proportion of C57 alleles increased with successive backcrosses it was noted that 
the phenotype worsened and mice started to seizure and die prematurely. In this 
thesis the appearance of the C57 mutants is compared with the C3H rsh, using the 
spinal cord as a representative tissue. The intention is not to provide a detailed 
description of the rumpshaker, as this has been published previously, but to 
highlight the new or different features of the mutation on the C57 background.
4.2.2 Materials and methods
4.2.2.1 Tissue preparation
The preparation of neural tissues for various purposes is described in (3.4. Tissue 
fixation, page 31 and 3.5. Tissue processing and sectioning, page 32). An 
investigation of the CNS materials was achieved on resin sections (1pm) stained 
with methylene blue/azure II (see 3.6.1.3, page 33) and paraffin sections stained 
with H&E (see 3.6.1.1, page 33).
4.2.2.2 Immunohistochemistry
Immunostaining was performed for PLP/DM20, MBP and GFAP as described for 
each individual marker in (3.8, page 34).
4.2.3 Results
4.2.3.1 Morphology
The general appearance of the C57 mutants was similar to that of the C3H mutants 
with obvious dysmyelination (Figure 9, page 57) characterised by naked axons 
surrounded by astrocyte processes or uncompacted oligodendrocyte processes 
(Figure 10, page 58). Any myelin sheaths present were thin for the axonal diameter 
and the myelin tended to be loose and undulating, sometimes containing vacuoles 
(Figure 11, page 59). Astrocyte processes were sometimes present between the axon 
and surrounding myelin or oligodendrocyte process (Figure 12, page 59). Overall, 
the amount of myelin appeared less in the C57 rsh with more naked axons and 
thinner sheaths. Pyknotic glial nuclei were evident in both mutants (Figure 9, page 
57) but clearly more frequent in the C57 mice. The number of microglial nuclei was 
increased in the C57 rsh and many microglia/macrophages had foamy or vacuolated 
cytoplasm due to lipid droplets and/or membranous inclusions (Figure 13, page 
60;).
4.2.3.2 Immunostaining
MBP immunostained collars were visible around many axons of varying sizes in 
both mutants. However, intense immunostaining was seen in ventral column of C3H 
rsh spinal cord compared with the C57 mutant. Many axons in C57 rsh appeared 
unassociated with MBP, due to the lack of myelin sheath or presence of very thin 
myelin sheaths in C57 rsh. In contrast, the normal mice contained many MBP 
immunostained myelin sheaths. The difference between the mutants and age- 
matched normal animals in MBP immunostained sections is evident (Figure 14, 
page 61). Immunostaining of sagittal brain and transverse spinal cord sections of 
C3H rsh and C57 rsh with PLP/DM20 and MBP showed variation between the 
mutants (Figure 15, page 62) with the intensity of staining for both proteins being 
greater in the C3H rsh.
Immunostaining for GFAP was performed to provide an indication of the 
distribution and reactivity of astrocytes in brain and spinal cord. The intensity of 
GFAP staining was moderately increased in the white matter o f both mutants 
relative to their wild types (data not shown); however there was no consistent 
difference between the two rumpshaker strains (Figure 16, page 63).
4.2.4 Discussion
Myelination occurs predominantly in the postnatal period in rodents, coinciding 
with the period of major expression o f the Pip gene. Thus, mutations in the Pip gene
result in varying degrees of myelin deficit in neurological mutants although the 
lethality of these mutations does not correlate with the beginning or even the stage 
of active myelination. Analysis of the pathology of mutant animals revealed that 
jimpy, the classic Pip mutant, has severely reduced amounts of myelin in the CNS 
white matter and the myelinated axons are found in low numbers (Sidman et a l, 
1964; Duncan, 1990). The C3H xsh has a much less severe phenotype than jimpy  
with considerably more myelin, a lack of seizures and normal longevity. Some 
findings from the current study suggest that C57 rsh is not closely similar to jimpy  
but at other levels, it is closer to jim py  than to the original C3H rsh. It is possible 
that C57 rsh could be positioned between the more severe jim py  and the mild C3H 
rsh phenotypes. In jimpy, many axons are, in fact, surrounded by a single layer of 
myelin sheath (Hirano et a l, 1969). This feature is also seen in C57 rsh, although 
many of the sheaths are thicker than those found in jimpy. Furthermore, myelin 
lamellae wrap loosely around the axon with fewer turns than normal and are 
vacuolated in both C57 rsh and jim py  (Nagara and Suzuki, 1982). In areas where 
the compacted myelin sheaths are found in rumpshaker, the IPL may appear normal 
regardless o f dysmyelination, or its spacing may be reduced (Griffiths et a l, 1990). 
This contrasts with jim py  where, if  myelinated areas are found, the IPL is fused to a 
single electron dense line (Duncan et a l ,  1987; Duncan et a l ,  1989). Overall, the 
C57 rsh has more myelin than the jim py  and jimpy-msd mutant mice although the 
clinical presentation is very similar. Interestingly, the C57 rsh also has more myelin 
than the shiverer mouse, an M6^-deletion mutant, which die at approximately 4-5 
months of age (Chemoff, 1981). The amount of myelin, therefore, does not 
necessarily correlate closely with the longevity of the animal (Billings-Gagliardi et 
a l,  1999; W olf et a l,  1999). The exact pathological basis for both seizures and 
death is not well understood in any of the myelin mutants.
Immunostaining results o f PLP and MBP in the C3H rsh in this thesis agree with 
the previous findings (Griffiths et a l,  1990; Fanarraga et a l,  1992) and extend this 
to demonstrate the further marked reduction in the C57 rsh. Myelin sheaths from 
both strains of rumpshaker immunostain for PLP/DM20 in contrast to the jimpy 
mouse in which there is an absence of staining (Sorg et a l, 1986). The results of the 
GFAP immunostaining were somewhat surprising. In general terms, the intensity of 
reaction correlates with the severity of phenotype; thus, in the jim py  mouse there is 
intense astrocytosis and GFAP staining (Skoff, 1976; Vela et a l, 1998). In the case 
of the rumpshaker, the intensity of GFAP stain appears similar in the white matter 
of both mutants and this is supported by the western blotting studies (see 4.4.3.2, 
page 97). However, there is not necessarily a direct link between dysmyelination 
and astrocytosis; in the severely dysmyelinated shiverer mouse there is little 
increase in astrocyte markers (Jacque et a l, 1986; Chen et a l, 1993). The role of the
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astrocyte reaction in Pip mutants is still unclear. While the astrocyte changes may 
be purely a reaction to the myelin changes and apoptosis there are also suggestions 
that this cell may be more intimately involved in the pathogenesis (Skoff, 1976; 
Knapp et a l ,  1993; Knapp and Skoff, 1993), despite the lack o f Pip gene expression 
in the astrocyte. The astrocyte has also been implicated as the source of the GRO-1 
chemokine, involved in stimulating the proliferation of oligodendrocyte progenitors, 
and whose levels are markedly elevated in the jim py  spinal cord (Wu et a l ,  2000).
The number and morphology of microglia/macrophages also differs between the 
two strains of rumpshaker. The morphological features do not allow us to determine 
whether the cells are derived from resting microglia or from monocytes of 
haematogenous origin. We found no evidence for “typical macrophages” within the 
myelin sheath, as found in classic inflammatory demyelinating disorders and little 
evidence o f such cells in a perivascular location. We suspect that most of these cells 
are derived from endogenous microglia. Although the absolute number is greater in 
the white matter o f the C57 mutant it is the morphological difference that is more 
striking. The frequency of cells with foamy cytoplasm and lipid and membranous 
inclusions is considerably higher in the C57 rumpshaker. Occasional cells also 
appear to have an additional pyknotic nucleus, suggesting they may have ingested 
an apoptotic cell. Similar microglia are also found in the jimpy mouse. The 
microglia/macrophage in the Pip mutants may fulfil more than one role. There is 
evidence for phagocytosis of apoptotic cells, probably oligodendrocytes (Vela et a l, 
1996). The lipid and membranous inclusions may indicate that they are involved in 
catabolism o f myelin lipids. Microglia are also a rich source of pro-inflammatory 
cytokines and, although this aspect has not been investigated in Pip mutants, it is 
possible they may contribute to the dysmyelination rather than just respond to it.
In summary, the general neuropathology suggests that the C57 rsh has few if  any 
unique features compared with its 0 3 H counterpart; rather, the common parameters 
differ quantitatively and qualitatively between the two mutants. However, the 
dissimilarity does not, at first impression, appear sufficient to explain the very 
marked difference in clinical features and outcome. For example, the exact 
pathological basis for both seizures and death in the 057 rsh is difficult to explain 
and indeed, the reasons for these features in any of the Pip mutant animals have not 
been adequately described.
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Fig. 9. Dysmyelination in mutant mice. Ventral column o f  
spinal cord from wild type (A), C3H rsh (B) and C57 rsh (C). 
There appears to be marginally more myelin in the C3H 
mutant. A pyknotic nucleus is shown (arrow). Resin section 
(lum ), Bar = 20um.
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Fig. 10A, B. Electron micrographs o f spinal cord from 
C3H and C57 rsh. Numerous naked or thinly sheathed 
axons are present. Bars = 2um.
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Fig. 11. Electron micrograph o f C57 rsh spinal cord at P20. Axon (A l) is 
surrounded by uncompacted oligodendrocyte prcesses and axon (A2) by a 
thin undulating myelin sheath.
Fig. 12. Electron micrograph o f C57 rsh spinal cord at P20. The axon is 
surrounded by oligodendrocyte processes and a thin sheath. An astrocye 
process (arrow) is present within the sheath. Bars = lum.
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Fig. 13 A. Electron micrographs of microglial cell. The cytoplasm 
contains numerous lipid and membranous inclusions. Bar = lum; 
Fig. 13B. Cytoplasm of microglial cell. The various inclusions are 
shown at higher magnification. Bar = 2um.
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Fig. 14. MBP immunostaining. Resin sections o f 
ventral column of spinal cord immunostained for
MBP. Bars = 20um
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PLP/DM20
C3H rsh C3H rsh
C57 rsh C57 rsh
MBP
C 3H  rsh C3H rsh
C57 rsh C57 rsh
Fig. 15. Immunostaining for PLP/DM20 and MBP. Saggital brain and 
transverse spinal cord sections of C3H and C51 rsh at P20. Bars cord = 
0.5mm; brain = 2mm.
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C 3H  rsh C 3H  rsh  ^ 
*
Fig. 16. Immunostaining for GFAP in spinal cord and brain of 
C3H and C57 mutants. The intensity and extent o f staining is 
greater in the C3H rsh. Bar cord = 0.5mm; brain = 2mm.
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4.3 Quantitative studies in rumpshaker
4.3.1.1 Introduction
Myelination is a feature of both CNS and PNS, Within the former, there is a very 
definite spatiotemporal pattern of myelination in which the spinal cord, particularly 
the cervical region, is one of the earliest sites. Most mammalian CNS axons are 
myelinated and the functions and structure of myelin have been described 
previously (see 1.8 The axon, page 7 and 1.10 Myelin sheath, page 9). Myelin is 
made up of lipids and proteins, of which PLP is the major component; thus, 
abnormalities in its molecular structure could result in phenotypic deficits. As 
defects in myelination or loss of formed myelin are associated with clinical deficits 
the differences between C3H and C57 rumpshaker mice might be reflected in 
differences in the amount of myelin. To evaluate the amount of myelin, myelin 
volume and myelin areas were measured in the ventral cervical spinal cord o f both 
strains o f wild type and mutant mice.
4.3.1.2 Materials and Methods
4.3.1.2.1 Myelin volume and myelin area
The estimation of myelin areas was made at PI 5, P20, P25 and P30 as described in 
(3.9.1, page 42). Myelin volume was calculated only in the mutant mice at P20 and 
P30 as described in (3.7.4, page 34).
4.3.1.3 Results
4.3.1.3.1 Myelin areas
The myelin areas were estimated in resin sections immunostained for MBP at P I5, 
P20, P25 and P30. The two strains o f wild types showed an identical profile. An 
obvious difference was noted between the mutant animals and their normal 
littermates at all ages examined. A significant reduction was noted between C57 rsh 
and C3H rsh (Figure 17, page 67).
4.3.1.3.2 Myelin volume
The volume of myelin present in the ventral column of cervical spinal cord of the 
two mutants at P20 and P30 was estimated by point counting of compact myelin 
using electron micrographs. The myelin volume was significantly reduced by 
approximately 50% in C57 rsh over C3H rsh (Figure 18, page 67).
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4.3.1.3.3 Percentage of myelinated axons
Using the same EM micrographs used for myelin volume quantification, the 
percentage o f myelinated axons was considered. It was 38 ± 3.2%; (M ± SEM, n = 
4) in C3H rsh whereas this was significantly decreased in C57 rsh 19.77 + 2.6%, (M 
± SEM, n = 4).
4.3.1.4 Discussion
Mutations o f the Pip gene result in severe myelin deficits. The degree of 
dysmyelination varies between mutants and although the C3H rsh represents one of 
the least severe phenotypes, there is still a significant myelin deficit. The C57 rsh 
was more severely affected than C3H rsh with approximately half the amount of 
myelin of the C3H rsh. A heterogeneous population of myelinated axons was found 
in rumpshaker. In C3H rsh, the majority of axons were myelinated whereas in C57 
rsh a smaller percentage were surrounded by myelin and naked axons were seen 
frequently in the spinal cord white matter. In both mutants the majority of sheaths 
were disproportionately thin for the axonal diameter although in smaller axons the 
deficit appeared less obvious; the sheath thickness was not quantified.
The jimpy, jimpy-msd and jimpy~4j represent the most severely affected Pip mutant 
animals, showing little myelin in the CNS (Duncan et a l, 1989; Duncan, 1990; 
Billings-Gagliardi et a l, 1995). In contrast, the C57 rsh has more myelin than any 
of these mutants although the clinical presentation is very similar. Interestingly, the 
C57 rsh also has more myelin than the shiverer mouse, an A%?-deletion mutant, 
which die at approximately 4-5 months of age (Chemoff, 1981). It seems probable 
that the presence of lengths of naked axon interspersed with thinly sheathed areas is 
responsible for some of the clinical signs, for example the tremor. However, 
whether the difference in amounts o f myelin is enough to explain the seizures in one 
strain of rumpshaker is more debateable. The amount o f myelin does not necessarily 
correlate closely with the longevity of the animal and several mutants with extended 
lifespan and virtually no myelin, have been described (Billings-Gagliardi et a l,  
1999; Wolfed a/., 1999).
Myelin mutant animals have been used to explore the role of oligodendrocytes and 
compact myelin in determining the structure of axons, particularly in relation to the 
nodal/paranodal area or the axonal cytoskeleton. Many instances have employed 
shiverer (Sanchez et a l, 1996; Brady et a l,  1999; Rasband et a l, 1999a; Rasband et 
a l,  1999b; Tait et a l,  2000; Sanchez et a l, 2000; Boiko et a l,  2001) although the 
jimpy  mutant has also been used (Baba et a l, 1999; Jenkins and Bennett, 2002). 
Some diversity of opinion has resulted as to the necessity of compact myelin and/or 
oligodendrocyte processes in defining the molecular architecture of the
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nodal/paranodal area; one possible reason is that without ultiastructural studies in 
combination with the immunostaining procedure, it is very difficult to decide if  a 
single layer o f oligodendrocyte process is present. The aspect of nodal organisation 
and molecular composition in rumpshaker has not been investigated in the present 
thesis, but is an aspect worthy o f future study.
MBP+ myelin 67
800
C3H WT 
C3H rsh 
C57 WT 
C57 rsh
(N
200
10 15 20 25 30 35
Age
Fig. 17. M yelin area (defined as the area o f  M BP-stained m yelin per mm^ of 
ventral white matter) between P I5 and P30. The two wild types are identical 
and different from their respective mutants. The C3H rsh has more m yelin at 
all ages.
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Fig. 18. M yelin volum e, derived by point counting from electron micrographs. 
There is significantly more m yelin in the C3H rsh compared with the C57 mutant 
at both ages.
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4.3.2 Evaluation of total glial cell and oligodendrocyte numbers
4.3 .2 .1  In trod u ction
Diseases of the CNS, of various aetiologies, may selectively produce changes in the 
numbers of neurons and glia. Spontaneous Pip gene mutations generally result in 
diffuse pathology affecting myelin-producing cells, the myelin itself and the 
supporting environment. There has been a long-standing debate as to whether the 
dysmyelination in Pip mutants is a direct result of apoptosis of oligodendrocytes 
and therefore a reduction in their numbers or whether the oligodendrocytes death 
and myelin deficit are not a direct cause and effect (Knapp et a l,  1986; Thomson et 
a l,  1999). In previous studies no reduction in oligodendrocyte numbers was 
detected in the C3H rsh (Griffiths et a l, 1990; Mitchell et a l , 1992; Fanarraga et 
a l, 1993). To re-evaluate this and to determine if  the same was true for the C57 
mutant the glial cell population was quantified in resin sections at various ages. 
Total glial cells and differential counts were considered in rumpshaker and wild 
types in both genetic backgrounds of mice. Additionally, the population of NG2+ 
oligodendrocyte progenitors was quantified.
4.3 .2 .2  M a ter ia l and  m ethods
4 .3 .2 .2 .1  G lia l cell q u an tifîca tion  in resin  sections
Total glial cell numbers and densities were estimated at PIG, P15, P20, P25 and P30 
as described in (3.7.1, page 33). The areas of the whole spinal cord and white 
matter, in transverse section were determined as described in (3.7.1, page 33).
4 .3 .2 .2 .2  D ifferen tia l cou n t o f  g lia l cells in resin  sections
Oligodendrocytes, astrocytes and microglia were counted differentially at P20 as 
described in (3.7.2, page 34).
4 .3 .2 .2  3 Q u an tifica tion  o f  A P C -p ositive  m ature o ligodend rocytes
Quantification of APC-positive mature oligodendrocytes was performed as 
described in (3.9.3, page 43).
4 .3 .2 .2 .4  Q u an tifica tion  o f  N G 2-p ositive  o ligodend rocyte  progen itors
Quantification of NG2-positive oligodendrocyte progenitors was performed as 
described in (3.9.4, page 43).
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4 .3 .2 .3  R esu lts
4 .3 .2 .3 .1  G lia l cell p op u la tion  (resin  sections)
The areas of the whole spinal cord and the white matter were measured in transverse 
section at the different ages studied. The white matter area increased steadily as the 
animal aged. After P I 5, the differences in white matter area between wild type and 
mutant were significant (Figure 19, page 73).
Total glial cell density was evaluated between PIO and P30. There was no 
difference between the C3H WT and the C57 WT at any age. The values in both 
mutants were significantly greater than their respective wild types at all ages. The 
values in the two mutants were similar at PIO; thereafter the density in the C57 rsh 
was elevated at P I5 and P20, similar at P25 and reduced at P30 compared with the 
C3H mutant (Figure 20, page 73).
Using the glial cell density in the ventral column and the white matter area the 
approximate total numbers of glial cells in the white matter per transverse section 
could be calculated. Total glial cell numbers were similar in both wild type strains 
and elevated in both mutants. The values in the C57 rsh were elevated at P20 and 
P25 compared with the C3H mutant (Figure 21, page 74).
4 .3 .2 .3 .2  D ifferen tia l cou n t o f  g lia l cells in resin  sections
A differential count of the glial population, based on cell morphology, was 
performed at P20. The specific interest at this stage was the number of 
oligodendrocytes present in the various genotypes. At this single time point, there 
was no difference in oligodendrocyte or astrocyte numbers between any of the 
genotypes. The number of microglia was elevated in both mutants relative to wild 
type (Figure 22,page 74).
4 .3 .2 .3 .3  A P C -p ositive  m atu re o ligodend rocytes
To provide a further independent marker for oligodendrocytes we used the APC 
antigen to quantify cells in the ventral columns between P I 5 and P30. Again, we 
determined cell density and total cell numbers. APC density (and total cells) was 
similar between both groups of wild type and stayed relatively constant between 
P I 5 and P30. In the C3H mutants the values were significantly elevated at P20 and 
P30 compared with their wild type. The C57 values were similar to the respective 
wild type at all ages but not different from the C3H rsh (Figure 23, page 75 and 
Figure 24, page 76).
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4.3 .2 .S .4  N G 2-p ositive  o ligod en d rocy te  p rogen itors
NG2+ cell density in the ventral white matter was similar in both groups of wild 
type, declining steadily between PI 5 and P30. The values in the C3H mutant were 
elevated over its wild type only at P30 whereas the C57 rsh was higher at all ages 
compared with wild type and with the C3H mutant (Figure 25, page 77).
4.3 2.4 D iscu ssion
Quantification of the total glial cell population in the spinal cord indicated that the 
mutant animals were significantly different from their respective normal littermates 
on both genetic backgrounds. Total glial cell numbers and density in C57 rsh were 
significantly increased over its C3H counterpart at P20 and P25. A similar pattern 
of increased glial cell density was reported in jim py  (Thomson et a l, 1999). 
Moreover, quantification o f EM images of shaking pup cervical spinal cord and 
optic nerve indicated an increase in glial numbers (Duncan et a l,  1983). It contrasts 
with the results obtained from EM thymidine autoradiographic study of md-mX optic 
nerve which showed no increase in glial cell numbers (Jackson and Duncan, 1988).
The total glial cells include oligodendrocytes, astrocytes, microglia and various 
immature and unidentifiable glia. The main focus in this section is on the 
oligodendrocyte lineage. The microglial population is discussed later (see 4.3.5, 
page 90). The astrocyte response is described in (4.2.4 Discussion, page 54).
As indicated in the Introduction, loss of mature oligodendrocytes has been 
implicated as the main reason for the hypomyelination in many of the animal and 
human Pip!PLP gene mutations, rumpshaker, on the C3H background, was 
described as a Pip mutant with normal or probably increased numbers of 
oligodendrocytes (Griffiths et a l ,  1990; Mitchell et a l ,  1992; Fanarraga et a l,  
1993); this finding was confirmed in the present study. The original quantification 
of cells was based largely on nuclear morphology in resin sections and comparative 
observations of electron micrographs. This approach has been criticised as not 
providing a definitive identification o f cell type. It is worth mentioning that 
whatever method is used there are always problematic areas; for example using in 
situ hybridization for Pip or immunostaining for PLP it can be difficult to 
differentiate a weak positive from a negative cell. To provide an independent 
assessment of oligodendrocyte numbers we used the recently described APC 
antigen to mark these cells (Bhat et a l, 1996; Fernandez et a l,  2000). We obtained 
similar results showing that in the C3H rumpshaker the number of APC+ cells was 
increased at peak myelination, relative to wild type.
If oligodendrocyte loss is critical in determining the overall phenotype, it should be 
evident in the C57 rsh. However, analysis of oligodendrocytes using both 
morphological and immunostaining criteria showed that their numbers were not 
reduced compared with wild type. The assessments suggested that the numbers of 
oligodendrocytes in the C3H rsh was greater than the C57 mutant at P20, but the 
difference was not significant. The main reason for the difference in total glial cell 
numbers between the two mutants reflects changes in the microglial population (see 
4.3.5, page 90). The data strongly support the argument that in rumpshaker a 
reduced number of oligodendrocytes is not the reason for the hypomyelination.
One problem in comparing oligodendrocyte numbers between different Pip mutants 
is that a variety of ages, locations and methods have been used, making it almost 
impossible to make meaningful comparisons. However, using in situ staining for 
galactcerebroside, it has been demonstrated that the oligodendrocyte number is not 
reduced in corpus callosum and cerebellum of P6, 10 and 15 jim py  mice (Ghandour 
and Skoff, 1988). Again in another species, the paralytic tremor rabbit, a 
combination of resin sections stained with toluidine blue and EM images from the 
dorsal funiculus of the cervical spinal cord, the intracranial portion of the optic 
nerve, and the middle portion of the anterior part of the corpus callosum at P8, 14 
and 90 suggested the number of oligodendrocytes was maintained (Taraszewska and 
Zelman, 1987). However, in the cervical spinal cord and optic nerve of shaking pup 
at 4 and 8 weeks there appeared to be decreased numbers of oligodendrocytes 
(Duncan et a l, 1983).
Developmentally, oligodendrocytes develop from progenitor cells, which in turn 
arise from precursor cells in the neuroepithelium. Until recently, these earlier stages 
have been difficult to identify in situ, due to a lack of suitable markers; antibodies 
such as A2B5 and 04 , which are used to surface stain cultured cells are difficult to 
use in tissue sections. The NG2 chondroitin sulphate proteoglycan has been found 
to label oligodendrocyte progenitors with a high degree of specificity (Stallcup and 
Beasley, 1987; Nishiyama et al., 1996). This marker has been used to demonstrate a 
vast anay of hitherto unrecognised cells in the parenchyma of animals and humans, 
including adults and the numbers o f such cells increase in association with disease 
or injury (Reynolds and Hardy, 1997; Keirstead et a l, 1998; Nishiyama et a l, 1999; 
Chang et a l, 2000; McTigue et a l, 2001). It is known to label blood vessels but 
distinguishing these from the progenitors is relatively straightforward. A very recent 
report has suggested macrophages may, in certain circumstances, express NG2 
(Jones et a l ,  2002), although other reports indicate that reactive microglia are not 
NG2+ (Nishiyama et a l,  1997). Interestingly, in the murine cerebral cortex two 
sub-populations of NG2+ progenitors have been described on the basis of presence
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or absence of expression of the Pip gene (Mahon et a l, 2002). Expression of NG2 
overlaps with the earlier PDGF a-receptor marker. Other markers such as the 
transcription factors Oligl and Glig2 and Nkx2.2 can be used to identify even 
earlier stages of the oligodendrocyte lineage. These were not used in the present 
study.
Although there are increased numbers of apoptotic glial cells, including 
oligodendrocytes, particularly in C57 rsh (see 4.3.3, page 78), the number of 
oligodendrocytes is not diminished. One possible reason is an increase number of 
progenitors that subsequently differentiate into oligodendrocytes. In keeping with 
this the NG2+ population was increased relative to wild type in the C57 rumpshaker 
between P I5 and P30 whereas only at the latter age was it elevated in the C3H 
mutant. Studies of oligodendrocyte progenitors in other Pip mutants have produced 
varying opinions. In many of the early studies the more definitive markers were not 
available. In the md-xdX the population of progenitors identified by PDGF a-receptor 
was reported as normal (Pringle et a l,  1997). In jimpy, progenitors (or presumed 
progenitors) are reported as being increased (Skoff, 1982; Wu et a l ,  2000). The 
increased number of progenitors in both jim py  and rumpshaker is associated with 
increased proliferation (see 4.3.4 Glial cell proliferation, page 84).
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Fig. 19. Area o f  white matter o f  transverse section o f  the cervical spinal cord 
between PIG and P30. The area in the C3H mutant is less than the respective wild  
type after P I5 whereas the C57 rsh is not different from its wild type except at P30. 
The two mutants differ only at P30.
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Fig. 20. Density o f  all glial ce lls in ventral white matter between PIO and P30. The 
two wild types are identical and differ from their respective mutants. The density 
in the C3H rsh is elevated relative to the C57 mutant at PI 5 and P20.
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Fig. 21. Total number o f  glial cells in white matter o f  transverse section o f  cervical 
cord between PIO and P30. The tw o wild types are identical and different from the 
mutants except at PIO. The tw o mutants differ from each other at P20 and P25.
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Fig. 22. Differential glial cell count at P20. There is no difference in the number of 
oligodendrocytes (O ligo) nor astrocytes (Astro). Both mutants have more microglia 
(M icro) than the respective wild types and the C57 rsh exceeds the C3H mutant.
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Fig. 23A . APC  density. Both C3H  and C 57 w ild  types are sim ilar at all ages but 
differ from their mutants at P I 5. The C3H  rsh is also significantly  different from  
this group o f  m ice at P 20-30.
APC+ cells
.S
c/3
700
-V-C3H WT 
-*-C 3 H  rsh 
C57 WT 
C57 rsh
600-
500-
400-
300-
200
10 20
Age (days)
30
Fig. 2 3 B. Total A P C + ce lls  in the w hite matter o f  transverse section  o f  cervical 
cord. There is no marked difference in the number o f  A PC  + ce lls  betw een the 
four groups o f  m ice at any age except at P30 where C3H  mutant is different 
from its C 57 counterpart.
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C 3II W T C3H rsh
Fig24A. Immunostaining for APC. Spinal cords from mice 
of all genotypes, aged P20, immunostained for APC. Bars 
= 0.5mm
Fig. 24B. Ventral column of white matter from C3H wild 
type and mutant mice immunostained for APC. Bars = 
lOOum.
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Fig. 25. N G 2+  ceil density. C3H W T and C 57 WT have a sim ilar NG2-t-cell density  
at all age and C3H  rsh up to P20. C 57 W T has less density than its mutant. The 
density o f  C 57 rsh appears higher than C3H  rsh at PI 5-20  but it is sim ilar at P30.
78
4.3.3 Glial cell apoptosis
4.3.3.1 Introduction
Programmed cell death or apoptosis, a complex mechanism, is seen widely in 
diseases and normal development. Histopathologically, it is characterised by nuclear 
pyloiosis, chromatin condensation, intact plasma membrane, cellular organelles and 
intracellular blebs (for review see Casaccia-Bonnefil, 2000). Mutations in the Pip 
gene result in a complex pathology including glial cell apoptosis (Skoff, 1995), 
presumably of oligodendrocyte lineages. Classical and immunostaining methods 
were applied to quantify apoptotic cells in the two mutants and their respective wild 
types. Attempts were also made to define the nature o f the dead cells by double 
labelling o f caspase-3-positive cells.
4.3.3.2 Material and methods
4.3.3.2.1 Quantification of pyknotic nuclei numbers
Quantification of Pyknotic nuclei numbers was performed as described in (3.7.3, 
page 34).
4.3.3.2.2 Quantification of Caspase-3-positive cells
Quantification of Caspase-3-positive apoptotic cells was performed as described in 
(3.9.5, page 43).
4.3.3.2.3 Identification of Caspase-3-positive glial cells
Double immunostaining of Caspase-3-positive glial cells for APC and CD45 was 
performed as described in (3.8.14, page 41).
4.3.3.3 Results
4.3.3.3.1 Pyknotic nuclei numbers
The numbers of dead cells between PIO and P30 was estimated by counting the 
number of pyknotic nuclei in all columns of the white matter in 1 pm resin sections 
(Figure 26, page 82). Values in both strains of wild type were similar, being 
maximal at PIO and then declining to P30. The numbers of pyknotic nuclei in the 
both mutants were increased over their wild types at P I5 and thereafter, by 
approximately two fold in C3H and seven fold in C57 rumpshaker. The difference 
between the two mutants was also significant between P I5 and P30.
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4.3.3.3.2 Caspase-3-positive apoptotic cells
In the resin sections the number o f pyknotic nuclei had been counted throughout all 
columns of white matter. In order to provide an estimate o f apoptotic cells in the 
ventral white matter we immunostained animals between PIO and P30 for caspase- 
3, an effector caspase, acting at a slightly earlier period of the pathway than the late- 
stage nuclear changes denoted by pyknosis. We calculated cell density and, from 
that value and the area, calculated the total numbers of cells in white matter; both 
parameters gave similar results. Surprisingly, the density of caspase-3+ cells in C3H 
wild type was significantly increased when compared with that of C57 wild type at 
PIO to P20 but similar at P30 (Figure 27, page 82). The values in the C3H rsh were 
increased over wild type between P I5 and P30 whereas the C57 mutant was 
increased at all ages relative to its wild type and to the C3H rsh.
4.3.3.3.3 Identity of the caspase-3-positive cells
After quantifying the level o f apoptosis using pyknotic nuclei and caspase-3- 
positive cells, the identity o f the dying cells was examined. The caspase-3-positive 
cells were double labelled with other markers to define the nature of the cells 
undergoing apoptosis. Cervical cord sections from C57 rsh at P I5 were selected, as 
this was an age and genotype of maximum involvement. Among the caspase-3- 
positive cells, 30.43% and 40.74% were APC-positive and CD45-positive cells, 
respectively ( Figure 28, page 83).
4.3.3.4 Discussion
This study has shown that programmed cell death is a predominant feature in the 
rumpshaker phenotype and that this process is particularly prominent in the C57 
mutant. In previous studies o f C3H rsh, cell death was not included as a feature 
(Griffiths et a l, 1990; Schneider et a l,  1992), an aspect which the present study has 
shown to be incorrect although the basic tenet of the previous studies, that the 
number of oligodendrocytes is not reduced, has been confirmed. Increased numbers 
o f dying cells is a feature o f the Pip mutants such as jim py  (Privât et a l,  1982; 
Knapp et a l,  1986; Knapp et a l ,  1990; Vermeesch et a l,  1990; Skoff and Knapp, 
1990) and md-rat (Boison and Stoffel, 1989; Lipsitz et a l ,  1998) and broadly 
correlates with the severity o f hypomyelination (Skoff, 1995). Similarly, in the 
present study the number of apoptotic cells was greater in the more severe 
phenotype. The dying cells in rumpshaker and other Pip mutations show the classic 
morphological changes of programmed cell death and activation of the caspase 
cascade. The TUNEL technique, which end labels cleaved DNA has also shown 
increased numbers o f labelled cells in Pip mutants (Skoff, 1995; Lipsitz et a l, 1998; 
Knapp et a l , 1999) although a close correlation between numbers of TUNEL+ cells
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and pylcnotic nuclei was lacking. These studies and others (Knapp et a l,  1986; 
Skoff, 1995; Gow et a l, 1998; Lipsitz et a l, 1998; Grinspan et a l,  1998; Beesley et 
a l,  2001) have indicated that the majority of dying cells were oligodendrocytes. As 
it is difficult to ascertain the nature o f the apoptotic cells by classical preparations 
we used double labelling to define the cell lineage of caspase-3-positive apoptotic 
cells in the rumpshaker. It was found that approximately 30% were APC+ 
oligodendrocytes and 40% labelled with the CD45 antigen. It is possible that some 
of the CD45+/caspase-3+ cells have in fact phagocytosed apoptotic 
oligodendrocytes and thus, the proportion of dead oligodendrocytes is higher than 
estimated. An attempt to double stain for NG2 and caspase-3 was unsuccessful as 
both antibodies were from the same species. It is unlikely that many NG2+ cells 
would have been apoptotic as cells undergoing this process are usually immature to 
early mature oligodendrocytes rather than progenitors (Grinspan et a l, 1998).
Only the cervical spinal cord was assessed for apoptotic cells in the present study 
but it is probably that similar features would have been evident throughout the CNS. 
However, in general, the timing of the apoptosis correlates with the temporal 
sequence of myelination (Knapp et a l,  1986; Skoff, 1995; Lipsitz et a l, 1998; 
Grinspan et a l, 1998) and would be expected to be later in brain regions.
Increased numbers of apoptotic oligodendrocytes are also found in Pip transgenics 
with increased dosage of the Pip gene (Readhead et a l,  1994; Inoue et a l, 1996; 
Anderson et a l, 1999; Bauer et a l,  2002) but not in Pip null mice (Klugmann et a l, 
1997; Yool et a/., 2001).
The mechanism of apoptosis in Pip mutations is not known. It may be linked to an 
“intrinsic toxicity” of the abnormal PLP product (Williams, II and Gard, 1997) or an 
accumulation of product in the RER (Gow et a l ,  1994b; Gow and Lazzarini, 1996; 
Gow et a l, 1998), possibly evoking an unfolded protein response (Southwood and 
Gow, 2001). In this hypothesis, changes in the frequency of apoptosis between 
mutations is ascribed to differences in the toxicity of the encoded PLP. It is also 
possible that the effect may be indirect; for example, the mutant oligodendrocyte 
may fail to establish proper connections with an axon and thus be deprived of 
critical trophic factors (Thomson et a l, 1999). This study suggests that if  the 
misfolded PLP is toxic to the cell it cannot be the only operating factor. If  it was, 
then one would expect the same frequency of apoptosis between the two 
rumpshakers as the primaiy, secondary and possibly the tertiary structure of the 
rumpshaker PLP should be identical.
Although increased death of oligodendrocytes is a feature of rumpshaker the 
oligodendrocyte numbers are maintained. This would argue that the apoptosis is not
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the primary direct cause of the dysmyelination, which must be related to a inability 
of the mutant oligodendrocyte to synthesise appropriate amounts of myelin. 
Nevertheless, the frequency of apoptosis in the more severe mutants is likely to 
compound the problem and may well contribute to the degree of dysmyelination, 
particularly as the condition advances.
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Fig. 26. Pyknotic nuclei in the w hite matter o f  transverse sections o f  cervical cord. 
A ll group o f  m ice appear sim ilar at PIO and the tw o w ild  types are identical at all 
ages. The difference in dead ce lls  is more obvious betw een  the tw o w ild  types and 
their mutants and betw een the tw o mutants th em selves from PI 5-30.
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Fig. 27. Total caspase-3 -t-cells. C3H  and C57 w ild  types are both show ing great 
sim ilarity in caspase-3 -t- ce lls  at all age. C3H  W T and its mutant are also similar 
at P I 0-20  but different at P30. Substantial d ifference is noted betw een C 57 WT 
and its mutant and the tw o mutants at all age except P20.
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Caspase-3 & APC
Caspase-3 & CD45
Fig. 28. Identification of caspase-3+ ceils. A. Ventral white 
matter from C57 rsh at P20, double stained with APC to show 
one oligodendrocyte (arrow) undergoing apoptosis together 
with an unidentified cell (arrowhead). B. Labelling o f ventral 
white matter from C3H rsh at P I5 for CD45 shows a 
caspase-3+ microglia/macrophage. Bars = lOum.
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4.3.4 Glial cell proliferation
4.3.4.1 In trod u ction
Neuroglia form a substantial part o f the cellular mass of the CNS. In normal 
development, proliferation of glial cell types, which is pronounced during the later 
stages of embryogenesis, declines after birth. The exact timing depends on both the 
CNS region and the cell type. In general terms astrocytes are generated prior to 
oligodendrocytes and the ventral spinal cord represents a region in which glial cell 
proliferation almost ceases within about 2 weeks of birth (Noll and Miller, 1993; 
Miller et ah, 1997; Calver et a l, 1998). However, occasional dividing glial cells are 
seen throughout the life o f animals (Homer et a l, 2000). Diseases of the CNS are 
often associated with proliferation of neuroglial cells, in particular microglia, 
astrocytes and, on limited occasions, cells of the oligodendrocyte lineage. Glial cell 
proliferation is common in dysmyelinating diseases. Using BrdU in vivo, neuroglial 
cell proliferation was investigated in rumpshaker and normal animals. Double 
labelling of BrdU-positive cells was also performed to define the nature of mitotic 
cells.
4 3,4 .2  M ater ia l and  m ethods  
4.3 .4 .2 .1  In jection  o f  m ice w ith  B rd U
Mice were injected intraperitoneally with BrdU as described in (3.1.4, page 28).
4.3 .4 .2 .2  Q u an tifica tion  B rd U  lab elled  nuclei
Quantification of BrdU labelled nuclei was performed as described in (3.9.2, page 
42).
4 .3 .4 .2 .3  Id en tifica tion  o f  dou b le  lab elled  B rd U -positive  g lia l cells
Double immunolabelling of BrdU-positive cells was performed as described in 
(3.8.13, page 41).
4.3 .4 .3  R esu lts
4 .3 .4 .3 .1  B rd U  lab elled  n u clei
In order to investigate the proliferation of cells in the white matter of the ventral 
cervical cord animals were pulse labelled with BrdU at ages between P5 and P30. 
All labelled cells were counted with no attempt to differentiate cell types; it was
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noted that very occasional endothelial cells were labelled but the vast majority of 
labelled cells were glial. In both strains o f wild type the profile was identical with 
maximum labelling between P5 and PIO followed by a sharp decrease to negligible 
levels at P30. The density of labelled nuclei and the labelling index (LI) were 
unchanged at P5 and PIO in C3H rsh but thereafter moderately elevated compared 
with the appropriate wild type. The values in the C57 mutant were raised at PIO and 
subsequently, compared with its wild type, and also increased in comparison with 
the C3H rsh (Figure 29, page 87 and Figure 30, page 88).
4 .3 .4 .3 .2  B rd U -p ositive  g lia l cells
The BrdU-positive cells were abundant in the cervical cord white matter o f the 
mutants, in particular at P15 and this age was selected to define the nature of the 
proliferating cells. Double immunolabelling for BrdU and APC, NG2 and CD45 
was performed at P I 5 in both mutants (Figure 31, page 89). As expected, few 
BrdU+ nuclei (<1%) were associated with APC+ oligodendrocytes. The proportions 
of BrdU+/NG2+ cells were 61.5 ± 2.4% and 43.0 ± 2.9% in C3H and C57 mutants, 
respectively. Taking into account the far greater number of BrdU-labelled nuclei in 
the C57 rsh, the actual number of proliferating NG2+ cells was ~ 1.5 fold greater 
than in the C3H rsh. The proportions of BrdU+/CD45+ cells were 7.3 ± 1.9% and 
22.8 ± 1.4%, respectively. As indicated above, occasional labelled endothelial cells 
were also seen. No attempt was made to identify other BrdU-labelled cells, such as 
astrocytes.
4.3 .4 .4  D iscu ssion
BrdU, an analogue of thymidine, is incorporated specifically into newly synthesised 
deoxyribonucleic acid (DNA), The incorporation of BrdU by proliferating cells and 
its detection using monoclonal antibodies has gained popularity as a reliable 
technique for identifying cells in the S (synthetic) phase o f the cell cycle (Magaud et 
a l, 1989). The BrdU LI and density are, in general, both increased in the mutant 
animals. Furthermore, the increase in these two variables is more marked in the C57 
rsh compared with the C3H rsh. This result is consistent with the increase in total 
glial cells in and between the two mutant strains identified by examining resin 
sections (see 4.3.2 Evaluation of total glial cell and oligodendrocyte numbers, page 
68) and is also in agreement with the previous finding (Fanarraga et a l, 1992). In 
the present study the cells were labelled for one hour with BrdU which is sufficient 
to label cells that have been within the S phase within that period; however, as the S 
phase represents about 1/3 of the cell cycle (depending on cell type) the actual 
number of proliferating cells will be considerably greater. Despite this caveat, the 
data do allow valid comparisons between the various genotypes. In general teiTns,
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the profile o f BrdU-labelled cells followed that for wild type but persisted for much 
longer. Even at P30 there were significant numbers of such cells in the C57 mutant. 
We have not followed the C3H rsh to older ages nor increased the duration of BrdU 
administration. It is quite possible that a heightened level of proliferation might 
persist into the adult mutant mouse. Recent studies in spinal cord and brain of 
normal rodents have identified slowly proliferating glial populations (Homer et a l, 
2000; Levine et a l, 2001).
Some other Pip gene mutants (for example jimpy and shaking pup) also display an 
increase in glial cell proliferation (Knapp et a l, 1986; Jackson and Duncan, 1988; 
Gencic and Hudson, 1990; Macklin et a l, 1991) whereas the md rat does not show 
an increase in total glial cell population (Jackson and Duncan, 1988; Boison and 
Stoffel, 1989).
The present study clearly identifies the NG2+ oligodendrocyte progenitor as one 
source of the BrdU-labelled nuclei. This is not unsurprising, as this cell type is 
Icnown to respond in myelin disorders (Keirstead et a l, 1998; Grinspan et a l, 1998; 
Di Bello et a l,  1999; Chang et a l, 2000). Increased proliferation is a means of 
maintaining (or restoring) the oligodendrocyte population in the presence of 
increased frequency of apoptosis.
The other labelled cell type was the CD45+ cell. In the rumpshaker it is probable 
that this marker identified predominantly microglia/macrophages rather than 
lymphocytes, as the labelling pattern correlated with F4/80 and few if  any 
lymphocytes were seen in resin sections.
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Fig. 29A . BrdU labelling index. A t P5, there is no significant d ifference  
betw een the w ild  types and the mutants. At P I 5 and thereafter, there is an 
increase in the labelling index in C 57 rsh over the tw o w ild  types and only  
at P30 a considerable difference is noted betw een C 57 rsh and C3H  rsh.
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Fig. 2 9 8 . BrdU + C ell density. BrdU density and L abelling index are sim ilar 
at P5. There is no d ifference betw een the w ild  types and C 3H  mutant. O f the 
group o f  m ice, C 57 mutant has significant increase in the density at PI 0-30  
but at P20 there no difference betw een the mutants.
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Fig. 30. Montage o f BrdU-labelled spinal cords at PIO. The 
difference in the number o f labelled nuclei between mutants and 
wild type and between mutants is shown.
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CD45 & BrdU
/
NG2 & BrdU
/
Fig. 31 A. Immunofluorescence for CD45 and BrdU. A 
double-labelled cell is indicated (arrow). Bar = 20um.
Fig. 3 IB. Immunofluorescence for NG2 and BrdU. Several 
double-labelled cells are shown (arrows). Bar = 50um.
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4.3.5 Macrophage/microglial cell response
4.3.5.1 Introduction
Macrophage/microglial cells represent the least common glial cell type in normal 
CNS and also have a different origin from the macroglia. However, in many 
diseases this cell population proliferates and/or activates depending on the cause(s) 
of the lesions. This population is potentially functional in some dysmyelinating 
diseases. In rumpshaker, macrophage/microglial cells are heavily dispersed in the 
white matter and less in the grey matter, especially in C57 strain. Using anti-CD45 
antibody, this population of cells was estimated. Additionally, the staining pattern 
of CD45 was compared with that of F4/80.
4.3.5.2 Material and methods
4.3.5.2.1 Quantification of CD45-positive microglia
Quantification of CD45-positive microglia was performed as described in (3.9.4, 
page 43).
4.3.5.2.2 Qualitative study of F4/80 and CD45-positive microglia
Immunostaining for F4/80-positive and CD45-positive microglial cells were 
performed as described in (3.8.5, page 39) and the sections were qualitatively 
investigated.
4.3.S.3 Results
4.3.5.3.1 CD45-positive microglia
Activated microphage/microglial cells were seen frequently in the resin sections o f 
rumpshaker particularly in the C57 mutants at P I5-30 (Figure 32, page 93 and 
Figure 33, page 94). To confirm this; CD45 antibody, a pan-leukocytic surface 
marker, was used to detect this particular type of cell population. The two groups of 
wild type appeared to have similar CD45+ cell density. The mutant mice had a 
significantly higher density than their respective wild types with C57 rsh being the 
highest. This value was higher in the C57 mutant than its C3H counteipart (Figure 
34, page 95).
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4,3.5.3.2 F4/80-positive and CD45-positive microglia
Of the surface markers found on the macrophages/microglial cells, F4/80 and CD45 
were used independently to detect this cell population. Brain and cervical cord 
sections from both mutants at P20 were immunostained with either marker using the 
ABC method. Interestingly, the intensity of F4/80 staining followed the same 
pattern as CD45 in both regions o f the CNS (data not shown).
4.3.S.4 Discussion
F4/80 represents a marker specific for microglia/macrophages (Perry et a l,  1985; 
Perry and Gordon, 1988) whereas CD45 additionally recognises lymphocytes. On 
resin sections and electron microscopy very few, if any lymphocytes were detected 
suggesting that the majority o f CD45+ cells were microglia/macrophages and, 
indeed, the staining pattern of the two markers was similar. As the staining intensity 
for CD45 was greater than F4/80, the former was used to simplify identification and 
quantification of cells.
Microglia form an important part of the cellular response to CNS dysmyelination. 
They are recruited in significant numbers to the site of lesions (Frank and Wolburg, 
1996). However, their responses not only includes an increase in actual numbers but 
also hypertrophy, change of gene expression with or without cellular proliferation 
and release of inflammatory cytokines. Macrophage/microglial cells in rumpshaker 
spinal cord showed considerable increases in their number. This result agreed with 
that result o f examining the resin sections (see 4.3.2.3.1 Glial cell population (resin 
sections), page 69). In this context, the jim py  mutant mouse also has a marked 
increase in macrophage/microglial cell population (Vela et a i, 1995). The early 
formation of a reserve of glial cells including microglia in mutant CNS may suggest 
a reciprocal temporal dialogue between these cells and, therefore, the microglial 
cells are in place to prepare for potential phagocytosis which may occur later when 
dysmyelination develops and the extent of the lesion increases, that is to say the 
dead cells. In rumpshaker, these cells not only increase in number, but also 
upregulate cell surface markers, such as CD45 and F4/80, during the course of the 
dysmyelination. The scattering of reactive microglia predominantly in the white 
matter tracts suggests that the signal for microglial reaction during this period may 
come locally from abnormally ensheathed or unsheathed axons. The unsheathed or 
abnormally wrapped axons of rumpshaker appear physically intact but are likely to 
be functionally abnormal as is the case in other dysmyelinating mutants, such as the 
shiverer mouse and m(7-rat (Kaplan et a l ,  1997; Brady et a l,  1999). The cross talk 
between abnormally functioning axons and microglia may initiate a microglial 
response. Additionally, the mutant oligodendrocytes may also contribute to
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triggering the microglial response. Another possible explanation for microglial 
response is the presence of the myelin debris and dead cells, which demanded fast 
removal. Morphologically, apoptotic cells are often seen within other cells at the 
light and electron microscopic levels. This observation is supported by double 
labelling of caspase-3-positive cells (see 4.3.3.4 Discussion, page 79) in which 
caspase-3-positive immunostaining was seen within CD45 positive cells. Although 
this might be explained by stimulation of microglial phagocytosis by dead cells and 
degenerated myelin, the numerous undigested debris in activated microglia suggest 
an active phagocytosis. However, the signals that lead to microglial activation and 
the functional consequences of microglial reaction remain to be understood. Finally, 
the high cellularity noted in the rumpshaker mutant animals is attributed largely to 
proliferation of macrophage/microglia cell series.
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Fig. 32. Montage o f CD45+ cells in spinal cord. Spinal 
cords from P20 C3H and C57 wild type and rumpshaker 
immunostained for CD45. Bars = 0.5 mm.
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Fig. 33A, B. Immunostaining for CD45 in dorsal columns o f C57 wild 
type (A) and rsh (B) at P20. The dorsal columns are outlined (arrows). 
Bars = lOOum.
Fig. 33C. Immunostaining for CD45 in ventral columns o f C57 rsh at 
P20. There is marked increase in the number and size o f the positive 
cells. Bar = lOOum.
Fig. 33D. Immunostaining for CD45 and DAPI in ventral columns of 
C57 rsh at P20. Two typical cells are indicated (arrows). Bar = 20um.
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Fig. 34. C D 45+ microglial cell density. C3H and C57 w ild types are both 
identical in their C D 45+cell density at P20-30. The mutants are significantly  
greater than the wild type groups. C57 rsh is obviously greater in its C D 45+  
cell density than C3H rsh especially at P20.
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4.4 Protein analysis
4.4.1 Introduction
The major myelin proteins in the CNS are PLP (see 1.12.5, page 11) and MBP (see 
1.12.3, Page 11). Several minor proteins are also found in myelin (see 1.12.1, page 
10; 1.12.2, page 10 and 1.12.4 page 11). Many diseases o f the CNS have been 
shown to involve these myelin proteins in man and animals. Abnormalities of 
myelin proteins were reported in various mutant mice such as jim py and shiverer. It 
was known from the previous investigations and the current study that rumpshaker 
has defective myelination in the CNS. In this study, immunoblotting analysis was 
used as another independent method to compare the abnormality in the expression 
o f myelin proteins and GFAP in the mutants and their respective normal littermate 
animals. Thus, analysis of myelin proteins and non-myelin proteins are important 
for understanding the pathology o f myelin-related diseases.
4.4.2 Material and methods
4.4.2.1 Protein analysis
Samples of the whole brain and spinal cord were homogenised, myelin extracted 
and the proteins were semi-quantified with Western blot using the anti-PLP C- 
terminal antibody, anti-MBP antibody, anti-MAG, anti-CNP and anti-GFAP 
antibody (see 3.11, page 44).
4.4.3 Results
4.4.3.1 Myelin proteins
The yield of purified myelin appeared similar in both wild types but was reduced in 
both mutants, particularly in C57 rsh. Semi-quantitative western blotting of myelin 
proteins revealed that the levels PLP/DM20 were markedly reduced in both mutants 
(<20%), with C57 rsh being lower than C3H rsh. However, in C3H rsh the levels of 
MBP, MAG and CNP were only minimally reduced. In contrast, all values were 
less than 40% of wild type in C57 rsh. (Figure 35, page 99; Figure 37, page 101). 
However, both wild types had the similar levels of PLP/DM20, MBP, CNP and 
MAG.
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4.4.3.2 GFAP
GFAP is the widely applicable marker of astrocytes in normal and diseased 
conditions. It was used in this study to evaluate the astrocytic response in the 
rumpshaker. There was a slight increase in GFAP bands of the mutant animals 
compared with wild types although the intensity appeared identical in both mutants. 
However, a minor, low molecular weight GFAP isoform was markedly increased in 
rumpshaker (Figure 36, page 100 and Figure 37, page 101).
4.4.4 Discussion
Biochemical analysis of dysmyelinating mutant animals gives an insight into the 
molecular mechanisms of gene expression, the structure-function relationship of 
myelin proteins and their interaction during normal myelin formation, rumpshaker 
shows dysmyelination in the CNS (see the results, 4.2.3.1 Morphology, page 54 and
4.2.3.2 Immunostaining, page 54) and this feature correlates the reduced amounts 
o f myelin extracted from these mutants with the C57 rsh being the more sevely 
affected. On the basis of the morphological parameters examined (see 4.3.1.3.1 
Myelin areas, page 64; 4.3.1.3.2 Myelin volume, page 64; and 4.3.1.3.3 Percentage 
o f myelinated axons, page 65), the reduction in the yield of purified isolated myelin 
from these mutants appeared to be mostly a consequence of reduction in both 
myelin sheath thickness and myelinated fibre number, particularly in C57 rsh.
Analysis o f protein levels in myelin show marked reduction in PLP with the C57 
rsh being more sevely affected. In contrast, MBP was minimally reduced in C3H 
rsh but in C57 rsh was less than 40% of its wild type. CNP and MAG were 
minimally reduced in C3H rsh whereas both proteins were substantially reduced in 
C57 rsh, compared with its normal littermates and CNP was lower than MAG. A 
previous study (Mitchell et a l,  1992) of the C3H rsh also found markedly reduced 
levels of PLP/DM20 but, in contrast to the present study, found lower levels of 
MBP (58%). Message levels of the two major proteins were not reduced to the same 
extent as the corresponding protein (Mitchell et a l, 1992). It is, therefore, clear that 
the rumpshaker mutation differentially influences the incorporation of myelin 
proteins into the sheath and does not solely reflect the overall dysmyelination. In the 
jim py  mutants of the Pip gene the amount of PLP was less than 1% and MBP was 
2% although CNP and MAG were 10% and 5%, respectively (Yanagisawa and 
Quarles, 1986). The jim py  mutation therefore has a very similar effect on the 
incorporation of all myelin proteins into the sheath.
Another possible explanation for the low levels of these proteins in rumpshaker and 
some Pip gene mutants might be due to failure of oligodendroblasts to differentiate 
into mature oligodendrocytes (Meier and Bischoff, 1975; Skoff, 1982). Since
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maximal synthesis of PLP lags behind MBP synthesis during normal development 
(Campagnoni and Hunkeler, 1980), it is possible that extremely low levels of PLP 
synthesis might be expected in oHgodendroglial cells that do not fully differentiate.
The morphological studies revealed little information regarding the astrocyte 
population and the immunohistochemistry suggested a moderate increase in GFAP 
but little difference between the mutants. GFAP immunoblotting was considered to 
extend these observations. The slight increase in GFAP coupled with no change in 
the number of astrocyte nuclei suggests that the astrocytes in rumpshaker increase 
expression of the Gfap gene, rather than proliferate. Since the response of GFAP is 
moderate and the fact that the astrocyte number is unchanged in both mutants, the 
astrocyte population may not be important in influencing the difference in 
phenotype.
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Fig. 35. Western blots o f  m yelin proteins in m yelin fractions from the spinal cords of 
P20 mice. Selected m yelin proteins were compared between the tw o mutants and their 
normal littermates. Data from 3 separate animals in each group is shown. The intensity 
o f  the mutant bands is reduced compared to normal animals. N onetheless the levels of 
myelin proteins are more markedly reduced in C57 rsh. (W: w ild type; R: rsh).
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Fig. 36. Western blots o f  GFAP from hom ogenates o f  P20 m ouse spinal cords. 
Data from 3 separate animals in each group is shown. There is a slight increase 
in the intensity o f  bands from the mutants, suggesting g liosis, but no obvious 
difference between the tw o mutants. (W: wild type; R: rsh).
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Fig. 37A . Sem i-quantification o f  myelin protein Western blots from P20 
m ouse spinal cords. The levels o f  m yelin proteins were reduced in the mutants. 
The obvious reduction in all protein is noted in C57 rsh particularly in 
PLP/DM 20.
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Fig. 37B. Sem i-quantification o f  GFAP Western blots from P20 m ouse spinal 
cords. Despite the minimal increase in GFAP, the tw o mutants appeared 
similar.
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5. Final discussion and future work
The accumulated data presented in this study, which is derived from the comparison 
of the phenotypes of rumpshaker mutation on two different genetic backgrounds, 
indicated that the same single mutation had more pronounced effects in the C57 
strain than the original C3H strain. Thus, the C57 rumpshaker is considered the 
severe phenotype of the mutation while the C3H rumpshaker is the mild form in 
terms of clinical manifestation and pathological findings. However, although there 
were quantitative and qualitative differences according to the present study, the 
similarities in response were more striking. Furthermore, this study adds weight to 
the contention that oligodendrocyte death and hypomyelination are two independent 
mechanisms with no direct relation between them. This study provided strong 
evidence that the oligodendrocyte population is maintained in the mutant 
rumpshaker. This study also emphasised that the severity o f the pathology 
correlates with the severity o f the phenotype, regardless o f its nature. This section 
aims to amalgamate the information accumulated from the phenotypic studies of 
rumpshaker mutation and to direct the prospective work.
The rumpshaker mutant animal is distinguishable from normal littermates at about 
P I0-13, by obvious tremors. The C57 rsh is also susceptible to seizures at about 
P25 with death by about a month of age. Despite the obvious clinical signs and 
pathology, it has proved difficult to correlate the two. It was not possible, because 
of time constraints to quantify changes or perform detailed neuropathology 
throughout all the CNS; therefore, the sampling of the CNS may be inadequate or 
the methods applied are not sensitive enough to detect the cause for all the clinical 
signs. For example, the techniques used with paraffin sections of the brain would 
not detect minute lesions or changes in soluble factors in certain tracts that might 
cause tremor and later severe seizures. Clearly, a more detailed study of other CNS 
regions would be useful.
The tremor is most probably related to the myelin deficit possibly leading to cross 
talk between axons. Detailed analysis of the ion channel distribution has not been 
performed in either strain of rumpshaker and, based on similar analyses in other 
myelin mutants (Wang et a l,  1995; Baba et a l,  1999; Rasband et a l,  1999b; Tait et 
a l,  2000; Rasband and Trimmer, 2001; Jenkins and Bennett, 2002), is likely to be 
abnormal. This may also be involved in the generation of the tremor, and possibly 
seizures, and is an area for future study. The changes which might be responsible
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for the tremors and/or seizures are very difficult to dissect with the methods used in 
this thesis. Other future studies might involve electrophysiological techniques or 
metabolic mapping to determine the site of origin of the seizures.
The underlying mechanism responsible for dysmyelination in the Pip mutant 
animals, including rumpshaker, is poorly understood. It has been demonstrated that 
oligodendrocytes differentiate and begin to synthesised myelin membrane 
components; unfortunately, they fail to complete this process (Koeppen et a l, 
1992). In this regard the expectation is that numerous oligodendrocyte progenitors 
arrive at their final destination and await a putative signal from either axons or 
generated in a cell-autonomous manner. At this point the scheduling of cell 
differentiation and maturation takes priority over cell division. The first cells that 
arrive manage to have that signal communication and to some extent are able to 
differentiate and mature to a level that produces the myelin sheaths seen in the 
mutant animals. The later arriving or dividing cells remain in continued 
proliferation due to the lack of the signal. Another potential explanation for 
dysmyelination is that astrocytic hypertrophy may interfere with oligodendrocyte 
contact with axons. Such a lesion has been recognised in jim py  mice (Skoff, 1976).
In vivo and in vitro studies provide evidence that PLP/DM20 protein trafficking is 
arrested in the RER preventing the elaboration o f myelin membranes in some of 
these mutants (Nussbaum and Roussel, 1983; Roussel et a l,  1987; Gow and 
Lazzarini, 1996; Gow et a l, 1998). However, it is not clear from these static images 
what happens to the PLP/DM20. This and previous studies have shown that the 
steady state levels of PLP and other myelin proteins are reduced in total CNS and 
myelin fractions of rumpshaker mice (Mitchell et a l ,  1992). The reduction in 
protein is disproportionate to the change in message levels and similar findings have 
been reported in the jim py  mouse (Sorg et a l, 1986; Sorg et a l,  1987). Ongoing 
studies in this unit using radioisotope incorporation have shown that the rate o f PLP 
synthesis is not decreased in rumpshaker, the same work has shown that the 
abnormal PLP appears to decay more rapidly than wild type PLP (Dr. Mark 
McLauchlin, unpublished data). An explanation for this view is that the synthesised 
PLP is rapidly degraded before reaching the membrane where it could incorporate 
into myelin sheath. An alternative explanation is that the PLP protein reaches the 
membrane, however, it fails to incorporate correctly into the myelin sheath in a 
stable manner, presumably due to abnormal conformational structure of the protein. 
Studies are ongoing to determine the intracellular dynamics of rumpshaker 
PLP/DM20 and what mechanism accounts for its rapid degradation. 
Immunostaining studies using the OlO antibody (Jung et a l ,  1996) applied to live 
cells has shown that approximately 60% to 70% of both C3H and C57 rumpshaker
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oligodendrocytes are surface labelled (Ian Griffiths, unpublished data). While the 
amount o f PLP reaching the membrane or the time taken was not determined, the 
study demonstrated that at least some PLP/DM20 was capable of inserting into 
myelin. Even at a simple level, the immunostaining of tissue sections performed in 
the current study showed that myelin sheaths were positive for PLP/DM20. It is 
possible that different “pools” of PLP/DM20 are present so that a fraction is 
degraded prior to reaching the membrane while another portion is turned over more 
rapidly from the myelin membrane. The isotope labelling studies previously 
mentioned should help determine the fate(s) of PLP/DM20. In normal myelin, it is 
believed that the PLP is important in maintaining the close apposition of the 
extracellular face of the lipid bilayer to form the double intraperiod line (Duncan et 
a l, 1987; Duncan et ah, 1989; Boison and Stoffel, 1994; Boison et a l, 1995; 
Klugmann et al., 1997). rumpshaker myelin has an abnormal intraperiod line 
(Griffiths et al., 1990) and this presumably reflects the decreased or 
disproportionate levels of PLP and DM20.
The role o f Pip gene mutations in programmed cell death (apoptosis) and survival 
of oligodendrocyte population is uncertain. However, it is clear that the frequency 
of apoptosis in APC+ oligodendrocytes is greater in the C57 compared with the 
C3H rumpshaker. Although the primary structure and presumably the secondary 
structure o f PLP/DM20 will be identical in both strains of rumpshaker it is possible 
that tertiary structure and also protein processing could be different between the two 
mutants. In Pip mutant animals oligodendrocyte death correlates with the 
expression o f PLP (Knapp et a l , 1986; Bongarzone et a l , 1997; Williams, II and 
Gard, 1997). However, evidence from gene targeted mice support the contention 
that oligodendrocytes survive in the absence of PLP protein (Klugmann et a l,  1997; 
Yool et a l ,  2001). Cell death in the Pip mutant animals, therefore, is due to causes 
other than insufficient functional PLP. Death in the oligodendrocyte lineage, 
perhaps due to misfolding o f PLP protein, raises at least two possibilities. One 
hypothesis suggests that oligodendrocyte death correlates with the PLP 
accumulation in the endoplasmic reticulum (Gow et a l,  1998) due to misfolding 
(Jung et a l ,  1996) The second possibility arises from the signalling components 
linking altered PLP synthesis to cell death. Misfolding of PLP and altered 
trafficking can be interpreted by the cell as stress signals originating from the 
endoplasmic reticulum and therefore activate two protein kinases called PERK and 
PKR, as part of the unfolded protein response (UPR), as shown in other systems. 
These kinases will then be responsible for the phosphorylation of the eIF-2 
translation factor, with direct consequential reduction of the translation rate as a 
way to protect the cell from additional accumulation of misfolded protein. In the 
case of severe endoplasmic reticulum stress, however, the cell may not be able to
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overcome the level of damage thus resulting in apoptosis, probably mediated by 
phosphorylation o f eIF-2 itself and potential involvement o f the transcriptional 
activator CHOP (Kaufman, 1999). The UPR can also activate caspase-12 (Rao et 
a l, 2001) and initiate the subsequent caspase cascade culminating in apoptosis. 
However, these scenarios are still theories in respect to the oligodendrocyte lineage 
and further study is required to evaluate their relevance. A further line of evidence 
speculates that the death of oligodendrocytes may involve a perturbed axo-glial 
relationship, an association that is necessary to ensure oligodendrocyte survival 
during normal myelinogenesis (Barres et a l,  1992; Barres and Raff, 1994; Barres 
and Raff, 1999). In contrast, mature oligodendrocytes seem more independent of 
axonal contact (McPhilemy et a l ,  1990; Ludwin, 1990). The inference from this 
data is that the oligodendrocytes die in the mutant animals from the lack of proper 
axonal contact, consequently no survival factors are delivered from axons, which 
are essential for the cells. This may explain the increase in number of apoptotic 
nuclei in C57 rsh compared to C3H rsh as the surface of contact with axons is much 
reduced due to abnormal contact o f axons with astrocytes and crowding of the white 
matter with proliferative glial cells, abnormal myelin debris and pyknotic nuclei. 
Again, in C57 rsh, the increased numbers of pyknotic nuclei may need not be due to 
exclusively to increased death o f cells but could be due to in part to a reduced rate 
of removal o f chromatin debris compared with C3H rsh. It is worth noting that these 
mutants at least share one common feature; namely, oligodendrocyte death, 
irrespective of at what stages of development and differentiation the particular cells 
undergo apoptosis. rumpshaker may provide a suitable model to test the hypothesis 
that intrinsic factors other than PLP may modify the cell fate from following the 
death pathways; instead of undergoing apoptosis the cell may continue to 
proliferate. Tissue culture could be used to investigate the role o f these postulated 
“other factors”.
Another interesting finding in the Pip mutant animals is the abundance of activated 
macrophage/microglial cells in the affected areas of the CNS. The origin of 
microglia CNS remains a controversial issue. These cells have the capacity to 
proliferate in the diseased CNS tissue and blood monocytes migrate to transform 
into macrophages in the injured CNS tissue (Perry and Gordon, 1988; Giulian, 
1995; Perry, 1996; Gonzalez-Scarano and Baltuch, 1999; Kaur et a l ,  2001). To- 
date, there are no available markers to discriminate the endogenous (proliferation of 
resident microglia) or exogenous (infiltration o f monocytes) origin o f a given 
reactive cell within the CNS, the specific contribution o f these two mechanisms 
seems to be closely related to the type of the lesion (Gonzalez-Scarano and Baltuch, 
1999; Stoll and Jander, 1999; Aldskogius, 2001). In dysmyelinating mutant animals, 
for instance rumpshaker, the blood brain barrier in the white matter areas remains
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relatively undisturbed as judged by morphological criteria, such as absence of 
oedema, although no definitive studies of its integrity have been conducted. The 
precise origin o f additional microglial/macrophage cells in this mutant remains to be 
elucidated. However, there are clues, such as the absence of inflammation 
(inflammatory reaction) elsewhere in the CNS, suggesting that the main source of 
reactive microglial/macrophages in rumpshaker is the proliferation of endogenous 
microglial cells. Additionally, the presence of BrdU+/CD45+ cells within one hour 
o f BrdU administration is probably too short a time for these cells to have 
originated from the blood. Further definitive studies to determine the origin of the 
CD45+ cells could involve labelling haematogenous cells or constructing chimeras 
with haemopoietic tissue of a different origin; although, until the importance of the 
response is established these studies are probably premature. The proliferation of 
microglial cells probably results from release of chemical mediators (cytokines). 
Moreover, activated microglia, and to some extent astrocytes, are a source of 
cytokines (Cross and Woodroofe, 2001; Gebicke-Haerter, 2001) that may adversely 
affect the pathogenesis of the dysmyelination. These cytokines may worsen the 
lesion through damaging myelin and possibly participating in inducing signals that 
stimulate apoptosis. The variability in degree of microglial response seems, 
however, to depend upon many complex factors including, age, type of lesion, CNS 
regions, species and the genetic background within species. Evidence for the 
influence of genetic background on the microglial response is obviously relevant in 
rumpshaker in which the C57 rsh shows more microglial cells in the white matter 
than C3H rsh. Overall, as with the deficit in myelin and glial death, the microglial 
response is parallel in the two mutants but considerably greater in C57 rsh. The 
importance of the microglial/macrophage activity in rumpshaker is worthy of 
further study and different strategies could be used to attenuate the microglial 
activity. For example, the anti-inflammatory antibiotic minocycline has been shown 
to reduce microglial-mediated damage in other CNS pathologies (Yijanheikki et a l,  
1999; Tikka et a l,  2001; He et a l, 2001; Tikka and Koistinaho, 2001). Various 
mutant mice deficient in key components of the leukocyte repertoire are available 
and could be crossed with the rumpshaker mice to determine if  this reduced the 
lesions.
This study also supports the glial proliferation compensation mechanism. In some 
dysmyelinating animals there is an increment in glial cell population, which is 
coupled with an increase in dead cells. This implies underlying mechanisms, which 
control the numbers o f the cells. There are several explanations for continued 
proliferation of glial cells. One possibility is that the competition for the inadequate 
available extracellular growth factors such as FGF and PDGF results in abnormal 
continued proliferation and death of glial cells. Lines of evidence support this view;
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for instance, vulnerability o f oligodendrocytes to apoptosis is prevented in an 
environment conditioned with basic FGF (Yasuda et ah, 1995). Additionally, 
providing jim py  oligodendrocytes with alternative environmental factors in vivo 
(Lachapelle et a l ,  1991) or medium conditioned by cell lines which express normal 
products o f the Pip gene in vitro (Knapp et a l, 1999), increases their survival. An 
abnormal microenvironment where the mutant oligodendrocytes develop could 
contain factors or signals responsible for glial cell proliferation and/or apoptosis. 
The GRO-1 chemokine which stimulates proliferation of oligodendrocyte 
progenitors is increased in jim py  spinal cords (Wu et a l, 2000). The 
microenvironmental factors and/or feedback signal pathways from the degenerative 
neural tissue seem to be particularly important for glial proliferation and/or death. 
The more realistic conclusion for the glial proliferation and/or death is that there is a 
cross talk between the survival and death factors or signals, which might be 
mediated by any of the normal Pip gene products in some stages. Interestingly, a 
soluble product of the Pip gene representing a C-terminal fragment, has been stated 
to have mitotic activity (Yamada et a l ,  1999) although this function was not 
retained by mutant proteins, including rumpshaker (Yamada et a l,  2001).
Additionally, differentiation and maturation of glial cell lineages in dysmyelinating 
mutant animals have received little attention over the last period. The scientists 
involved have been more interested in studying the most advanced stages of the 
pathology in these mutants (for instances the abnormalities o f myelin, proliferation 
or apoptosis o f glial cell lineages, etc.) trying to explore the possible function of 
PLP/DM20. DM20 is an alternative transcript of the PLP; the significance of its 
appearance at mid-gestation (Timsit et a l,  1992; Timsit et a l ,  1995; Dickinson et 
a l,  1996; Spassky et a l, 1998) prior to the onset of normal myelination in mice, is 
unknown. One possible opinion is that DM20 may have a role in the differentiation, 
maturation and specification of various systems in the embryos. As this protein or 
message is expressed specifically in the oligodendrocyte lineage within the CNS 
one might expect its influence to be on differentiation and maturation of these cells 
and on myelination. In the case of Pip gene mutant animals, oligodendrocyte 
progenitors may continue to proliferate rather than differentiate and mature, due to 
the abnormal DM20 message or protein. Thus, a population of cells which is 
dividing without differentiation can obviously produce more cells over a period of 
time than one in which cells differentiate and exit the cell cycle, as in normal 
development. Another interesting possibility is that abnormal DM20 may delay the 
differentiation and maturation by some modification or suppression events.
Although severity o f the phenotypes still considers an open question. Example of 
the mild form or severe form of the disease is well demonstrated in rumpshaker in
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which C3H rsh (mild) and C57 rsh (severe). Similarly, in humans the mild form is 
SPG2 while the more severe form is PMD. To address such a question, it would be 
useful to understand the correlation between the accumulation of mutant DM20 and 
the severe phenotype as many studies provide some evidences that stressed its effect 
on the resultant phenotypes of the mutation. A strong correlation between the 
accumulation of mutant forms of DM20 in the RER and severe disease in humans 
has been proposed (Tosic et a l ,  1996; Gow and Lazzarini, 1996; Tosic et a l ,  1997). 
Using the COS-7 cells, the non-oligodendrocyte related system, it has been 
domenstrated that only mutations associated with severe disease in patients interrupt 
DM20 trafficking and cause the protein to accumulate in the RER (Gow and 
Lazzarini, 1996; Southwood and Gow, 2001); mutations that do not perturb DM20 
trafficking cause mild forms of the disease. This suggests that either the 
accumulation o f DM20 may be extremely toxic to cells and further increases the 
vulnerability o f oligodendrocytes to apoptosis or that failure to transport DM20 to 
the cell membrane is necessary for normal function. In other words, mutations that 
interrupt the trafficking of both PLP and DM20 can be viewed simply as causing 
more pronounced manifestations of the phenotypes than those that are observed in 
mildly affected human patients. In this perspective, the disease process can be 
largely accounted for by an accumulation of mutant PLP in the perinuclear region of 
oligodendrocytes and additional accumulation of mutant DM20 simply increases 
severity (Southwood and Gow, 2001). In relation to the above view, 
immunoblotting suggests that the amount o f PLP in C57 rsh is 50% of that of C3H 
rsh. The amount of DM20 is 2/3 reduced in C57 rsh compared with its C3H 
counterpart. This data, if  interpreted in favour of the previously mentioned 
explanation, should be treated with care as one expected that the compartmental 
arrest of DM20 mirrors the severity o f the phenotype in C57 strain. In contrast, C3H 
rsh has minor alteration in the level of DM20, thus, the phenotype is mild. Thus, 
tracing the Pip gene products in the different strains o f rumpshaker would clarify 
this theory.
The results from the current study provide further evidence that rumpshaker 
mutants are an appropriate model for SPG2 and PMD and are available for testing 
any hypothesis that could not easily be addressed in human materials. This mutation 
on both different genetic backgrounds embodies the broad spectrum of PMD/SPG2 
phenotypes in some, but not all, aspects. These two mutants provides advantages 
over each other in which C57 rsh could be used for studying some mechanisms 
such as apoptosis, macrophage/microglial response, proliferation or protein 
pathways, for example. Whereas the C3H rsh could be a useful model for testing 
some features, for instance, the differentiation and maturation of glial lineages in 
oligodendrocytes and the mechanisms or factors controlling these developmental
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processes under the influence of the mutation. Studying the genetic aspect in 
relation to the rumpshaker mutation on the two different genetic backgrounds could 
give us a clue to the genetic interactions that give rise to the divergent phenotypes.
Clearly, the time is now appropriate to initiate further studies into several aspects of 
the rumpshaker mutation, related to the phenotypic differences induced by the two 
genetic backgrounds. A mapping study to identify regions harbouring putative 
modifying loci, with the eventual aim of cloning the genes, is an immediate priority. 
The use o f new molecular tools of microarray and proteomics would seem 
appropriate to determine patterns o f gene expression that differ between the two 
strains. It is quite probable that some of these genes showing differences in 
expression will also correlate with those identified in the mapping study. The recent 
developments in mouse genomics make all these approaches viable options.
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6. Appendix 1
6.1.1 APES-coated slides
APES-coated slides were generally used for Immunohistochemistry because they 
keep the sections adhered. For cleaning grease, slides were soaked overnight in 5% 
Decon 90 (Decon Lab Ltd) and washed in distilled water and oven dried. The dried 
slides were then soaked in 0.25% APES (Sigma) in methylated spirit in a fiime hood 
for 2 minutes. Finally, the slides were rinsed in DEPC-treated water for 2 minutes 
and oven dried wrapped in foil. APES-coated slides were stored at room 
temperature.
6.1.2 DEPC-treated water
0.1% solution o f DEPC was made in distilled water and left for at least 12 hours to 
inactivate contaminating RNases. The water was autoclaved at ISlb.in'^ for 20 
minutes to destroy the DEPC before use and stored sealed at room temperature until 
require.
6.1.3 Fixatives
6.1.3.1 Karnovsky’s modified fixative (paraformaldehyde/glutaraldehyde
4%/5%)
Preperation of 500 ml of the fixative:
8% Paraformaldehyde: 20 g of paraformaldehyde was added to 250 ml of dH20 and 
heat to 65°C. Few drops of IM  NaOH was added to clear and solution was allowed 
to c o o l.
0.08M Cacodylate buffer: 17.1224 sodium cacodylate was dissolved in a 1 litre of 
dH20 and adjusted to pH 7.2.
250 ml 8% paraformaldehyde
100 ml 25% glutaraldehyde
150 ml 0.08M cacodylate buffer
250 mg Calcium chloride
I l l
Add volumes, dissolve calcium choride, adjust to pH 7.2, filter, and store 
at 4%.
6.1.3.2 4% paraformaldehyde
Preperation of 500 of the fixative:
20g paraformaldehyde was added to 500ml PBS and heat to 65°C. Few drops of IM 
NaOH were added to clear the solution, filtered, cooled, and adjusted to pH 7.2.
6.1.3.3 Periodate-Iysine-paraformaldehyde (P-L-P) fixative
Preperation of 1 litre of the fixative:
Buffered lysine solution: 13.7g lysine monohydrate dissolved in 375ml dHzO. 1.8g 
sodium hydrogen phosphate dissolved in 100ml dH20. The two solutions were 
mixed to give 475ml and pH 7.4
10% Paraformaldehyde: 20g paraformaldehyde dissolved in 200 ml dH20 and 
heated to 65°C. Few drops of IM  NaOH were added to clear and allowed to cool.
The two solutions were separately stored at 4°C overnight. Immediately before use 
the two solutions were mixed and the final volume is made up to 1 litre using O.IM 
phosphate buffer. 2.14g sodium periodate was also dissolved .
6.1.3.4 Buffered neutral formaldehyde
Preperation of 1 litre o f the fixative:
100 ml 40% formaldeyde (Merck)
900 ml tap water
4 g sodium dihydrogen phosphate
8 g di-potasium hydrogen phosphate
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6.1.4 Tissue processing protocols
6.1.4.1 Paraffin wax processing
BNP fixed materials were passed through below various solutions and finally 
blocked in paraffin wax.
NB: Necoloidine (Merck) solution for microscopy was considered to be a 100% 
celloidin, therefore, 1ml was added per 100ml methyl benzoate.
1- 70% methylated spirit/5 % phenol 2 hr room temperature
2- 90% methylated spirit/5 % phenol 2hr room temperature
3- methylated spirit 2hr room temperature
4- ethanol/5 % phenol 2hr room temperature
5- ethanol/5 % phenol Ihr room temperature
6- ethanol/5 % phenol Ihr room temperature
7- 1% celloidin in methyl benzoate 4hr room temperature
8- xyelene Ihr room temperature
9- xyelene Ihr room temperature
10- xyelene Ihr room temperature
11- paraffin wax 6hr 60°C
12- paraffin wax 6hi’ 60°C
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6.1.4.2 Resin processing
CNS tissues were passed through below various solutions and finally blocked in 
resin:
1- isotonic cacodylate buffer 50 min 4°C
2- 1% 0 s 0 4  in cacodylate buffer 2hr room temperature
3- isotonic cacodylate buffer 30 min room temperature
4- 50% ethanol 5 min 4°C
5- 50% ethanol 10 min 4°C
6- 70% ethanol 5 min 4°C
7- 70% ethanol 10 min 4°C
8- 80% ethanol 5 min 4°C
9- 80% ethanol 10 min 4°C
10- 90% ethanol 5 min 4°C
11- 90% ethanol 10 min 4°C
12 ethanol 20 min 4°C
13 ethanol 20 min 4°C
14- propylene oxide 15 min room temperature
15- propylene oxide 15 min room temperature
16- 1:2 resin: propylene oxide 13 hr room temperature
17- 1:1 resin: propylene oxide 6 hr room temperature
18- 2:1 resin: propylene oxide 18hr room temperature
19- resin 4 hr 30°C
Isotonie cacodylate buffer:
16.05 g sodium cacodylate
3.8 g sodium chloride
0.055 g calcium chloride
0.102 g magnesium chloride
Dissolved in 1 litre dH20 and adjusted to pH 7.2
Araldite resin:
1- 30 g araldite CY212 (resin)
2- 25.2 g dodecanyl succinic anhydride
3- 1.2 ml 2,4,6-tri-dimethylaminomethyl-phenol
4- 0.75 ml di-butylphthalate
Add land 2, place in an oven at 65°C for 10-15 min and mix. Add 3 and 4, and 
Stear until mixure well homogenised and stored at -20°C.
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6.1.5 Staining protocols
6.1.5.1 Dewaxing and rehydration of paraffin sections
1- xylene 2 mins
2- absolute alcohol 2 mins
3- methylated spirits 2 mins
4- water 2 mins
5- Lugols iodine 1 min
6- water 1 min
7- 5% sodium thiosulphate 1 min
8- water 2 mins
6.1.5.2 Dehydration and cleaning of sections
1- methylated spirits 2 mins
2- absolute alcohol 2 mins
3- absolute alcohol 2 mins
4- histoclear 2 mins
5- xylene 2 mins
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6.1.5.3 Haematoxylin and eosin
1- xylene 2 mins
2- absolute alcohol 2 mins
3- methylated spirits 2 mins
4- water 2 mins
5- Lugols iodine 1 min
6- water 1 min
7- 5% sodium thiosulphate 1 min
8- water 2 mins
9- Mayers haematoxylin 10 mins
10 1% acid alcohol 3 dips
11- water 2 mins
12- Scots tap water substitute 1 min
13- water 2 mins
14- methylated spirits 10 secs
15- saturated alcoholic eosin 2 mins
16- methylated spirits 10 secs
17- absolute alcohol 2 mins
18- histoclear 2 mins
19- xylene 5 mins
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6.1.5.4 Haematoxylin
1- Running water 2 mins
2- Mayers haematoxylin 50 secs
3- water wash off excess haematoxylin
4- Scots tap water substitute 30 secs
6.1.5.5 Staining for electron microscopy
1- saturated uranyl acetate in 50% ethanol 15 min
2- 50% ethanol rinse
3- 50% ethanol rinse
4- dHiO rinse
5- dHzO rinse
6- air dry
7- Reynold’s lead citrate (Sodium 
Hydroxide moistened chamber)
10 mins
8- IM sodium hydroxide rinse
9- IM sodium hydroxide rinse
10- IM sodium hydroxide rinse
11 dHzO Several rinses
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Reynold’s lead citrate (1.2mM lead citrate, 1.8mM sodium citrate, pH 
12.0)
1- 1.33 g lead nitrate dissolved in 15 ml dH20 1 min vigorous shaking
2- 1.76 g sodium citrate dissolved in 15 ml dH20 1 min vigorous shaking
Add 1 to 2 and equilibrate over 30 minutes with occasional shaking. Clear with IM 
NaOH and make up to the final volume of 50 ml with dH2Ü.
6.1.6 Staining solutions
6.1.6.1 Methylene blue/ azure II
1% methylene blue
1% azure II
1% borax
diluted dH2 0  and filtered before use 
6.1.6.2 Mayers haematoxylin
1 g haematoxylin
10 g potassium alum
0.2 g sodium iodate
in 1 litre of dH2 0 , bring to boiling point, allow to cool overnight, and then add:
1 g citric acid
50 g chloral hydrate
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6.1.6.3 Scots tap water substitute
3.5 g sodium bicarbonate
20 g magnesium sulphate
in 1 litre of (IH2O
6.1.7 General Buffers
6.1.7.1 Phosphate buffer saline (PBS)
8 g sodium chloride
1.44 g disodium hydrogeg phosphate
0.24 g potassium dihydrogeg phosphate
0.2 g potassium chloride
Dissolved in 800 ml of dH20, adjusted to pH 7.4 with IM HCl and the volume 
made up to 1 litre with dH2 0
6.1.7.2 11 M phosphate buffer
77.4 ml IM  disodium hydrogeg phosphate
22.6 ml IM  potassium dihydrogeg phosphate
combined two volumes and adjusted to pH 7.4 with IMHCl 
6.1.7.3 Tris buffer saline
3 g tris base pH 7.5
8 g sodium chloride
0.2 g potassium chloride
dissolved in 800 ml of dH20, adjusted to pH 7.4 with IM HCl and the volume made 
up to 1 litre with dH2 0 .
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6.1.7.4 Tris-EDTAbu
500 lal IM  tris pH 8.0
100 pi 0.5M EDTA
Ter (TE buffer)
Volume made up to 50 ml with dHzO
6.1.7.5 Tris acetate EDTA buffer xlO (TAE buffer)
48.4 tris base
11.4 ml glacial acetic acid
20 ml 0.5M EDTA
Volume made up to 1 litre with dHzO
7. Appendix 2. Details of statistical 
analyses
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8. Abbreviations
ABC avidin biotine complex
APC adenomatous polyposis and somatic mutations
AOI area of interest
APES 3 -aminopropyltriethoxy-silane
BNF buffered neutral paraformaldehyde
bp base pair
BrdU bromodeoxy Uridine
02 second segment of cervical cord
CD45 leukocyte cell surface glycoprotein
C3H rsh C3H/101 rumpshaker
C3HW T C3H/101 wild type
CNP 2,3, cyclic nucleotide 3-phosphodiesterase
CNS centi'al nervous system
C57 rsh C57BL/6J rumpshaker
C57 WT C57BL/6J wild type
DAP 3,4,3,4,-teraminobiphenyl hydrochloride
DAPI 4,6-diamidino-2-phenylindole
dHzO distilled water
DM20 26.5 kDa protein isoform encoded by Pip gene
DNA deoxyribonucleic acid
dNTP deoxynucleoside triphosphate
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DTT dithiothreitol
EDTA ethylene-di-amine-tetra-acetate
EM electron microscope
F4/80 a 160 kD glycoprotein expressed by murine macrophages
FGF fibroblast growth factor
FITC fluorescein isothiocyanate
GC galactocerebroside
gDNA genomic deoxyribonucleic acid
GFAP glial fibrillary acidic protein
H&E haematoxylin and eosin
HRP horseradish peroxidase
HSPGs heparan sulphate proteoglycans
IPL intraperiod line
IGF insulin growth factor
KDa kiloDalton
LI labelling index
LM light microscope
M molar
MAG myelin-associated glycoprotein
MBP myelin basic protein
MDL major dense line
ml millilitre
IÛ micromillilitre
mg milligram
i  J U
mM millimolar
pm micromillimetxe
MOBP myelin-associated oligodenrocytic basic protein
MOG myelin/oligodendrocyte glycoprotein
MOSP myelin oligodendrocyte specific protein
mRNA messenger ribonucleic acid
NG2 integral membrane chondroitin sulfate proteoglycan
NGS normal goat serum
OMGP oligodendrocyte myelin glycoprotein
OSP oligodendrocyte specific protein
P postnatal
PAP peroxidase-anti-peroxidase
PBS phosphate buffered saline
PCR polymerase chain reaction
PDGFRa platelet-derived growth factor A
PLP proteolipid protein (30kDa protein)
P-L-P periodate-lysine-paraformaldehyde
PLP proteolipid protein (human gene)
Plp proteolipid protein (non-human gene)
PljJP jimpy
jimpy-4j
Plp/^ly jim py  male
pyp^^ jimpy  heterozygote
pyp-^nsd myelin synthesis deficient
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Plp"'“ myelin deficient
P l f f paralytic tremor
pyp-rsh rumpshaker
rumpshaker male
pljJp-rM* rumpshaker heterozygote
pljJP-'^ l^pljJP-r l^' rumpshaker homozygote
Plp*'* wild type
PMD Pelizaeus-Merzbacher disease
PNS peripheral nervous system
POA proligodendroblast antigen
PVDF polyvinylidene fluoride microporous membrane
RA retinoic acid
RER rough endoplasmic reticulum
RNA ribonucleic acid
RNase ribonuclease
rpm revolution per minute
rsh rumpshaker
SDS sodium dodecyl sulphate
SDS-PAGE sodium dodecyl sulphate polyarylamide gel eletrophoresis
Sec second
s.e.m standard error of the mean
SPG2 Spastic Paraplegi Type 2
SrDM20 soma-restricted DM20 protein isoform
SrPLP soma-restricted PLP protein isoform
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TAE
Taq
TBS
TEMED
TxR
U
UlsnRNP
UPR
UTR
UV
tris acetate ethylene-di-amine-tetra-acetate buffer 
themophilus aquaticus 
tris buffered saline
N,N,N,N’, tetramethylethylenediamine
Texas red
unit
U 1 small nuclear ribonucleoproteins 
unfolded protein response 
untranslated region 
ultraviolet
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